id	sid	tid	token	lemma	pos
dpc-4893	1	1	dermatology	dermatology	NOUN
dpc-4893	1	2	:	:	PUNCT
dpc-4893	1	3	practical	practical	ADJ
dpc-4893	1	4	and	and	CCONJ
dpc-4893	1	5	conceptual	conceptual	ADJ
dpc-4893	1	6	research	research	NOUN
dpc-4893	1	7	letter	letter	NOUN
dpc-4893	2	1	|	|	ADV
dpc-4893	2	2	dermatol	dermatol	ADJ
dpc-4893	2	3	pract	pract	NOUN
dpc-4893	2	4	concept	concept	NOUN
dpc-4893	2	5	.	.	PUNCT
dpc-4893	3	1	2025;15(1):4893	2025;15(1):4893	NUM
dpc-4893	3	2	1	1	NUM
dpc-4893	3	3	real	real	ADJ
dpc-4893	3	4	-	-	PUNCT
dpc-4893	3	5	life	life	NOUN
dpc-4893	3	6	experience	experience	NOUN
dpc-4893	3	7	of	of	ADP
dpc-4893	3	8	bimekizumab	bimekizumab	NOUN
dpc-4893	3	9	in	in	ADP
dpc-4893	3	10	27	27	NUM
dpc-4893	3	11	obese	obese	ADJ
dpc-4893	3	12	patients	patient	NOUN
dpc-4893	3	13	with	with	ADP
dpc-4893	3	14	plaque	plaque	NOUN
dpc-4893	3	15	-	-	PUNCT
dpc-4893	3	16	type	type	NOUN
dpc-4893	3	17	psoriasis	psoriasis	NOUN
dpc-4893	3	18	:	:	PUNCT
dpc-4893	3	19	a	a	DET
dpc-4893	3	20	24	24	NUM
dpc-4893	3	21	-	-	PUNCT
dpc-4893	3	22	week	week	NOUN
dpc-4893	3	23	multicenter	multicenter	NOUN
dpc-4893	3	24	retrospective	retrospective	ADJ
dpc-4893	3	25	study	study	NOUN
dpc-4893	3	26	zeno	zeno	PROPN
dpc-4893	3	27	fratton1	fratton1	PROPN
dpc-4893	3	28	,	,	PUNCT
dpc-4893	3	29	vincenzo	vincenzo	NOUN
dpc-4893	3	30	maione2	maione2	PROPN
dpc-4893	3	31	,	,	PUNCT
dpc-4893	3	32	stefano	stefano	PROPN
dpc-4893	3	33	bighetti2	bighetti2	PROPN
dpc-4893	3	34	,	,	PUNCT
dpc-4893	3	35	luca	luca	PROPN
dpc-4893	3	36	bettolini2	bettolini2	PROPN
dpc-4893	3	37	,	,	PUNCT
dpc-4893	3	38	giuseppe	giuseppe	PROPN
dpc-4893	3	39	stinco1	stinco1	PROPN
dpc-4893	3	40	,	,	PUNCT
dpc-4893	3	41	enzo	enzo	NOUN
dpc-4893	3	42	errichetti1	errichetti1	PROPN
dpc-4893	3	43	1	1	NUM
dpc-4893	3	44	institute	institute	NOUN
dpc-4893	3	45	of	of	ADP
dpc-4893	3	46	dermatology	dermatology	NOUN
dpc-4893	3	47	,	,	PUNCT
dpc-4893	3	48	department	department	NOUN
dpc-4893	3	49	of	of	ADP
dpc-4893	3	50	medicine	medicine	NOUN
dpc-4893	3	51	,	,	PUNCT
dpc-4893	3	52	university	university	PROPN
dpc-4893	3	53	of	of	ADP
dpc-4893	3	54	udine	udine	PROPN
dpc-4893	3	55	,	,	PUNCT
dpc-4893	3	56	italy	italy	PROPN
dpc-4893	3	57	2	2	NUM
dpc-4893	3	58	dermatology	dermatology	NOUN
dpc-4893	3	59	department	department	NOUN
dpc-4893	3	60	,	,	PUNCT
dpc-4893	3	61	university	university	NOUN
dpc-4893	3	62	of	of	ADP
dpc-4893	3	63	brescia	brescia	PROPN
dpc-4893	3	64	,	,	PUNCT
dpc-4893	3	65	asst	asst	PROPN
dpc-4893	3	66	spedali	spedali	PROPN
dpc-4893	3	67	civili	civili	PROPN
dpc-4893	3	68	di	di	PROPN
dpc-4893	3	69	brescia	brescia	PROPN
dpc-4893	3	70	,	,	PUNCT
dpc-4893	3	71	brescia	brescia	PROPN
dpc-4893	3	72	,	,	PUNCT
dpc-4893	3	73	italy	italy	PROPN
dpc-4893	3	74	key	key	PROPN
dpc-4893	3	75	words	word	NOUN
dpc-4893	3	76	:	:	PUNCT
dpc-4893	3	77	bimekizumab	bimekizumab	NOUN
dpc-4893	3	78	,	,	PUNCT
dpc-4893	3	79	biologic	biologic	NOUN
dpc-4893	3	80	,	,	PUNCT
dpc-4893	3	81	obese	obese	ADJ
dpc-4893	3	82	,	,	PUNCT
dpc-4893	3	83	psoriasis	psoriasis	NOUN
dpc-4893	3	84	,	,	PUNCT
dpc-4893	3	85	safety	safety	NOUN
dpc-4893	3	86	citation	citation	NOUN
dpc-4893	3	87	:	:	PUNCT
dpc-4893	3	88	fratton	fratton	PROPN
dpc-4893	3	89	z	z	PROPN
dpc-4893	3	90	,	,	PUNCT
dpc-4893	3	91	maione	maione	NOUN
dpc-4893	3	92	v	v	NOUN
dpc-4893	3	93	,	,	PUNCT
dpc-4893	3	94	bighetti	bighetti	PROPN
dpc-4893	3	95	s	s	PROPN
dpc-4893	3	96	,	,	PUNCT
dpc-4893	3	97	bettolini	bettolini	PROPN
dpc-4893	3	98	l	l	NOUN
dpc-4893	3	99	,	,	PUNCT
dpc-4893	3	100	stinco	stinco	ADJ
dpc-4893	3	101	g	g	PROPN
dpc-4893	3	102	,	,	PUNCT
dpc-4893	3	103	errichetti	errichetti	PROPN
dpc-4893	3	104	e.	e.	PROPN
dpc-4893	3	105	real	real	ADJ
dpc-4893	3	106	-	-	PUNCT
dpc-4893	3	107	life	life	NOUN
dpc-4893	3	108	experience	experience	NOUN
dpc-4893	3	109	of	of	ADP
dpc-4893	3	110	bimekizumab	bimekizumab	NOUN
dpc-4893	3	111	in	in	ADP
dpc-4893	3	112	27	27	NUM
dpc-4893	3	113	obese	obese	ADJ
dpc-4893	3	114	patients	patient	NOUN
dpc-4893	3	115	with	with	ADP
dpc-4893	3	116	plaque	plaque	NOUN
dpc-4893	3	117	-	-	PUNCT
dpc-4893	3	118	type	type	NOUN
dpc-4893	3	119	psoriasis	psoriasis	NOUN
dpc-4893	3	120	:	:	PUNCT
dpc-4893	3	121	a	a	DET
dpc-4893	3	122	24	24	NUM
dpc-4893	3	123	-	-	PUNCT
dpc-4893	3	124	week	week	NOUN
dpc-4893	3	125	multicenter	multicenter	NOUN
dpc-4893	3	126	retrospective	retrospective	ADJ
dpc-4893	3	127	study	study	NOUN
dpc-4893	3	128	.	.	PUNCT
dpc-4893	4	1	dermatol	dermatol	NOUN
dpc-4893	4	2	pract	pract	PROPN
dpc-4893	4	3	concept	concept	NOUN
dpc-4893	4	4	.	.	PUNCT
dpc-4893	5	1	2025;15(1):4893	2025;15(1):4893	X
dpc-4893	5	2	.	.	PUNCT
dpc-4893	6	1	doi	doi	NOUN
dpc-4893	6	2	:	:	PUNCT
dpc-4893	6	3	https://doi.org/10.5826/	https://doi.org/10.5826/	PROPN
dpc-4893	6	4	dpc.1501a4893	dpc.1501a4893	ADV
dpc-4893	6	5	accepted	accept	VERB
dpc-4893	6	6	:	:	PUNCT
dpc-4893	6	7	september	september	PROPN
dpc-4893	6	8	30	30	NUM
dpc-4893	6	9	,	,	PUNCT
dpc-4893	6	10	2024	2024	NUM
dpc-4893	6	11	;	;	PUNCT
dpc-4893	6	12	published	publish	VERB
dpc-4893	6	13	:	:	PUNCT
dpc-4893	7	1	january	january	PROPN
dpc-4893	7	2	2025	2025	NUM
dpc-4893	7	3	copyright	copyright	NOUN
dpc-4893	7	4	:	:	PUNCT
dpc-4893	7	5	©	©	PROPN
dpc-4893	7	6	2024	2024	NUM
dpc-4893	7	7	fratton	fratton	PROPN
dpc-4893	7	8	et	et	PROPN
dpc-4893	7	9	al	al	PROPN
dpc-4893	7	10	.	.	PUNCT
dpc-4893	8	1	this	this	PRON
dpc-4893	8	2	is	be	AUX
dpc-4893	8	3	an	an	DET
dpc-4893	8	4	open	open	ADJ
dpc-4893	8	5	-	-	PUNCT
dpc-4893	8	6	access	access	NOUN
dpc-4893	8	7	article	article	NOUN
dpc-4893	8	8	distributed	distribute	VERB
dpc-4893	8	9	under	under	ADP
dpc-4893	8	10	the	the	DET
dpc-4893	8	11	terms	term	NOUN
dpc-4893	8	12	of	of	ADP
dpc-4893	8	13	the	the	DET
dpc-4893	8	14	creative	creative	ADJ
dpc-4893	8	15	commons	common	NOUN
dpc-4893	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4893	8	17	license	license	NOUN
dpc-4893	8	18	(	(	PUNCT
dpc-4893	8	19	by	by	ADP
dpc-4893	8	20	-	-	PUNCT
dpc-4893	8	21	nc-4.0	nc-4.0	NOUN
dpc-4893	8	22	)	)	PUNCT
dpc-4893	8	23	,	,	PUNCT
dpc-4893	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4893	8	25	,	,	PUNCT
dpc-4893	8	26	which	which	PRON
dpc-4893	8	27	permits	permit	VERB
dpc-4893	8	28	unrestricted	unrestricted	ADJ
dpc-4893	8	29	noncommercial	noncommercial	ADJ
dpc-4893	8	30	use	use	NOUN
dpc-4893	8	31	,	,	PUNCT
dpc-4893	8	32	distribution	distribution	NOUN
dpc-4893	8	33	,	,	PUNCT
dpc-4893	8	34	and	and	CCONJ
dpc-4893	8	35	reproduction	reproduction	NOUN
dpc-4893	8	36	in	in	ADP
dpc-4893	8	37	any	any	DET
dpc-4893	8	38	medium	medium	NOUN
dpc-4893	8	39	,	,	PUNCT
dpc-4893	8	40	provided	provide	VERB
dpc-4893	8	41	the	the	DET
dpc-4893	8	42	original	original	ADJ
dpc-4893	8	43	authors	author	NOUN
dpc-4893	8	44	and	and	CCONJ
dpc-4893	8	45	source	source	NOUN
dpc-4893	8	46	are	be	AUX
dpc-4893	8	47	credited	credit	VERB
dpc-4893	8	48	.	.	PUNCT
dpc-4893	9	1	funding	funding	NOUN
dpc-4893	9	2	:	:	PUNCT
dpc-4893	9	3	none	none	NOUN
dpc-4893	9	4	.	.	PUNCT
dpc-4893	10	1	competing	compete	VERB
dpc-4893	10	2	interests	interest	NOUN
dpc-4893	10	3	:	:	PUNCT
dpc-4893	10	4	none	none	NOUN
dpc-4893	10	5	.	.	PUNCT
dpc-4893	11	1	authorship	authorship	NOUN
dpc-4893	11	2	:	:	PUNCT
dpc-4893	11	3	all	all	DET
dpc-4893	11	4	authors	author	NOUN
dpc-4893	11	5	have	have	AUX
dpc-4893	11	6	contributed	contribute	VERB
dpc-4893	11	7	significantly	significantly	ADV
dpc-4893	11	8	to	to	ADP
dpc-4893	11	9	this	this	DET
dpc-4893	11	10	publication	publication	NOUN
dpc-4893	11	11	.	.	PUNCT
dpc-4893	12	1	corresponding	correspond	VERB
dpc-4893	12	2	author	author	NOUN
dpc-4893	12	3	:	:	PUNCT
dpc-4893	12	4	zeno	zeno	PROPN
dpc-4893	12	5	fratton	fratton	PROPN
dpc-4893	12	6	,	,	PUNCT
dpc-4893	12	7	md	md	PROPN
dpc-4893	12	8	,	,	PUNCT
dpc-4893	12	9	institute	institute	PROPN
dpc-4893	12	10	of	of	ADP
dpc-4893	12	11	dermatology	dermatology	NOUN
dpc-4893	12	12	,	,	PUNCT
dpc-4893	12	13	department	department	NOUN
dpc-4893	12	14	of	of	ADP
dpc-4893	12	15	medicine	medicine	NOUN
dpc-4893	12	16	,	,	PUNCT
dpc-4893	12	17	university	university	PROPN
dpc-4893	12	18	of	of	ADP
dpc-4893	12	19	udine	udine	PROPN
dpc-4893	12	20	,	,	PUNCT
dpc-4893	12	21	piazzale	piazzale	PROPN
dpc-4893	12	22	santa	santa	PROPN
dpc-4893	12	23	maria	maria	PROPN
dpc-4893	12	24	della	della	PROPN
dpc-4893	12	25	misericordia	misericordia	PROPN
dpc-4893	12	26	,	,	PUNCT
dpc-4893	12	27	15	15	NUM
dpc-4893	12	28	.	.	NOUN
dpc-4893	12	29	33100	33100	NUM
dpc-4893	12	30	–	–	PUNCT
dpc-4893	12	31	udine	udine	PROPN
dpc-4893	12	32	,	,	PUNCT
dpc-4893	12	33	italy	italy	PROPN
dpc-4893	12	34	.	.	PUNCT
dpc-4893	13	1	phone	phone	NOUN
dpc-4893	13	2	:	:	PUNCT
dpc-4893	13	3	(	(	PUNCT
dpc-4893	13	4	+39	+39	PROPN
dpc-4893	13	5	)	)	PUNCT
dpc-4893	13	6	0432559822	0432559822	NUM
dpc-4893	13	7	.	.	PUNCT
dpc-4893	14	1	e	e	X
dpc-4893	14	2	-	-	NOUN
dpc-4893	14	3	mail	mail	NOUN
dpc-4893	14	4	:	:	PUNCT
dpc-4893	15	1	zenofratton@gmail.com	zenofratton@gmail.com	X
dpc-4893	15	2	introduction	introduction	NOUN
dpc-4893	15	3	psoriasis	psoriasis	NOUN
dpc-4893	15	4	is	be	AUX
dpc-4893	15	5	frequently	frequently	ADV
dpc-4893	15	6	linked	link	VERB
dpc-4893	15	7	to	to	ADP
dpc-4893	15	8	metabolic	metabolic	NOUN
dpc-4893	15	9	disorders	disorder	NOUN
dpc-4893	15	10	such	such	ADJ
dpc-4893	15	11	as	as	ADP
dpc-4893	15	12	diabetes	diabetes	NOUN
dpc-4893	15	13	,	,	PUNCT
dpc-4893	15	14	dyslipidemia	dyslipidemia	NOUN
dpc-4893	15	15	,	,	PUNCT
dpc-4893	15	16	and	and	CCONJ
dpc-4893	15	17	obesity	obesity	NOUN
dpc-4893	15	18	[	[	X
dpc-4893	15	19	1	1	NUM
dpc-4893	15	20	-	-	SYM
dpc-4893	15	21	4	4	NUM
dpc-4893	15	22	]	]	PUNCT
dpc-4893	15	23	.	.	PUNCT
dpc-4893	16	1	obesity	obesity	NOUN
dpc-4893	16	2	affects	affect	VERB
dpc-4893	16	3	around	around	ADP
dpc-4893	16	4	25	25	NUM
dpc-4893	16	5	%	%	NOUN
dpc-4893	16	6	of	of	ADP
dpc-4893	16	7	psoriasis	psoriasis	NOUN
dpc-4893	16	8	patients	patient	NOUN
dpc-4893	16	9	and	and	CCONJ
dpc-4893	16	10	is	be	AUX
dpc-4893	16	11	often	often	ADV
dpc-4893	16	12	associated	associate	VERB
dpc-4893	16	13	with	with	ADP
dpc-4893	16	14	poorer	poor	ADJ
dpc-4893	16	15	responses	response	NOUN
dpc-4893	16	16	to	to	ADP
dpc-4893	16	17	biologic	biologic	NOUN
dpc-4893	16	18	therapies	therapy	NOUN
dpc-4893	16	19	,	,	PUNCT
dpc-4893	16	20	especially	especially	ADV
dpc-4893	16	21	tnf	tnf	PROPN
dpc-4893	16	22	-	-	PUNCT
dpc-4893	16	23	α	α	PROPN
dpc-4893	16	24	and	and	CCONJ
dpc-4893	16	25	interleukin	interleukin	NOUN
dpc-4893	16	26	(	(	PUNCT
dpc-4893	16	27	il)-17	il)-17	NOUN
dpc-4893	16	28	-	-	PUNCT
dpc-4893	16	29	inhibitors	inhibitor	NOUN
dpc-4893	16	30	[	[	X
dpc-4893	16	31	1	1	NUM
dpc-4893	16	32	-	-	NUM
dpc-4893	16	33	5].1	5].1	NUM
dpc-4893	16	34	-	-	SYM
dpc-4893	16	35	4	4	NUM
dpc-4893	16	36	bimekizumab	bimekizumab	NOUN
dpc-4893	16	37	(	(	PUNCT
dpc-4893	16	38	bkz	bkz	PROPN
dpc-4893	16	39	)	)	PUNCT
dpc-4893	16	40	,	,	PUNCT
dpc-4893	16	41	a	a	DET
dpc-4893	16	42	monoclonal	monoclonal	NOUN
dpc-4893	16	43	antibody	antibody	NOUN
dpc-4893	16	44	targeting	target	VERB
dpc-4893	16	45	both	both	CCONJ
dpc-4893	16	46	il-17a	il-17a	PROPN
dpc-4893	16	47	and	and	CCONJ
dpc-4893	16	48	il-17f	il-17f	NOUN
dpc-4893	16	49	,	,	PUNCT
dpc-4893	16	50	has	have	AUX
dpc-4893	16	51	shown	show	VERB
dpc-4893	16	52	promising	promising	ADJ
dpc-4893	16	53	results	result	NOUN
dpc-4893	16	54	in	in	ADP
dpc-4893	16	55	the	the	DET
dpc-4893	16	56	treatment	treatment	NOUN
dpc-4893	16	57	of	of	ADP
dpc-4893	16	58	moderate	moderate	ADJ
dpc-4893	16	59	to	to	ADP
dpc-4893	16	60	severe	severe	ADJ
dpc-4893	16	61	psoriasis	psoriasis	NOUN
dpc-4893	16	62	in	in	ADP
dpc-4893	16	63	both	both	CCONJ
dpc-4893	16	64	clinical	clinical	ADJ
dpc-4893	16	65	trials	trial	NOUN
dpc-4893	16	66	and	and	CCONJ
dpc-4893	16	67	real	real	ADJ
dpc-4893	16	68	-	-	PUNCT
dpc-4893	16	69	world	world	NOUN
dpc-4893	16	70	studies	study	NOUN
dpc-4893	16	71	[	[	X
dpc-4893	16	72	6	6	NUM
dpc-4893	16	73	]	]	PUNCT
dpc-4893	16	74	,	,	PUNCT
dpc-4893	16	75	yet	yet	CCONJ
dpc-4893	16	76	specific	specific	ADJ
dpc-4893	16	77	data	datum	NOUN
dpc-4893	16	78	in	in	ADP
dpc-4893	16	79	obese	obese	ADJ
dpc-4893	16	80	patients	patient	NOUN
dpc-4893	16	81	are	be	AUX
dpc-4893	16	82	scarce	scarce	ADJ
dpc-4893	16	83	.	.	PUNCT
dpc-4893	17	1	case	case	NOUN
dpc-4893	17	2	presentation	presentation	NOUN
dpc-4893	17	3	this	this	DET
dpc-4893	17	4	24	24	NUM
dpc-4893	17	5	-	-	PUNCT
dpc-4893	17	6	week	week	NOUN
dpc-4893	17	7	retrospective	retrospective	ADJ
dpc-4893	17	8	study	study	NOUN
dpc-4893	17	9	,	,	PUNCT
dpc-4893	17	10	conducted	conduct	VERB
dpc-4893	17	11	at	at	ADP
dpc-4893	17	12	2	2	NUM
dpc-4893	17	13	italian	italian	ADJ
dpc-4893	17	14	dermatological	dermatological	ADJ
dpc-4893	17	15	centers	center	NOUN
dpc-4893	17	16	(	(	PUNCT
dpc-4893	17	17	udine	udine	PROPN
dpc-4893	17	18	and	and	CCONJ
dpc-4893	17	19	brescia	brescia	PROPN
dpc-4893	17	20	)	)	PUNCT
dpc-4893	17	21	,	,	PUNCT
dpc-4893	17	22	aims	aim	VERB
dpc-4893	17	23	to	to	PART
dpc-4893	17	24	evaluate	evaluate	VERB
dpc-4893	17	25	the	the	DET
dpc-4893	17	26	efficacy	efficacy	NOUN
dpc-4893	17	27	and	and	CCONJ
dpc-4893	17	28	safety	safety	NOUN
dpc-4893	17	29	of	of	ADP
dpc-4893	17	30	bkz	bkz	NOUN
dpc-4893	17	31	in	in	ADP
dpc-4893	17	32	obese	obese	ADJ
dpc-4893	17	33	patients	patient	NOUN
dpc-4893	17	34	with	with	ADP
dpc-4893	17	35	plaque	plaque	NOUN
dpc-4893	17	36	-	-	PUNCT
dpc-4893	17	37	type	type	NOUN
dpc-4893	17	38	psoriasis	psoriasis	NOUN
dpc-4893	17	39	.	.	PUNCT
dpc-4893	18	1	consecutive	consecutive	ADJ
dpc-4893	18	2	obese	obese	ADJ
dpc-4893	18	3	patients	patient	NOUN
dpc-4893	18	4	(	(	PUNCT
dpc-4893	18	5	body	body	NOUN
dpc-4893	18	6	mass	mass	NOUN
dpc-4893	18	7	index	index	NOUN
dpc-4893	18	8	[	[	X
dpc-4893	18	9	bmi	bmi	X
dpc-4893	18	10	]	]	X
dpc-4893	18	11	≥30	≥30	PROPN
dpc-4893	18	12	)	)	PUNCT
dpc-4893	18	13	with	with	ADP
dpc-4893	18	14	plaque	plaque	NOUN
dpc-4893	18	15	-	-	PUNCT
dpc-4893	18	16	type	type	NOUN
dpc-4893	18	17	psoriasis	psoriasis	NOUN
dpc-4893	18	18	of	of	ADP
dpc-4893	18	19	moderate	moderate	ADJ
dpc-4893	18	20	-	-	PUNCT
dpc-4893	18	21	to	to	ADP
dpc-4893	18	22	-	-	PUNCT
dpc-4893	18	23	severe	severe	ADJ
dpc-4893	18	24	entity	entity	NOUN
dpc-4893	18	25	(	(	PUNCT
dpc-4893	18	26	psoriasis	psoriasis	NOUN
dpc-4893	18	27	area	area	NOUN
dpc-4893	18	28	and	and	CCONJ
dpc-4893	18	29	severity	severity	NOUN
dpc-4893	18	30	index	index	NOUN
dpc-4893	18	31	(	(	PUNCT
dpc-4893	18	32	[	[	X
dpc-4893	18	33	pasi	pasi	NOUN
dpc-4893	18	34	]	]	X
dpc-4893	18	35	)	)	PUNCT
dpc-4893	18	36	>	>	X
dpc-4893	18	37	10	10	NUM
dpc-4893	18	38	)	)	PUNCT
dpc-4893	18	39	]	]	PUNCT
dpc-4893	18	40	or	or	CCONJ
dpc-4893	18	41	involving	involve	VERB
dpc-4893	18	42	“	"	PUNCT
dpc-4893	18	43	sensitive	sensitive	ADJ
dpc-4893	18	44	areas	area	NOUN
dpc-4893	18	45	”	"	PUNCT
dpc-4893	18	46	(	(	PUNCT
dpc-4893	18	47	scalp	scalp	NOUN
dpc-4893	18	48	,	,	PUNCT
dpc-4893	18	49	genitalia	genitalia	NOUN
dpc-4893	18	50	,	,	PUNCT
dpc-4893	18	51	palms	palm	NOUN
dpc-4893	18	52	/	/	SYM
dpc-4893	18	53	soles	sol	NOUN
dpc-4893	18	54	)	)	PUNCT
dpc-4893	18	55	treated	treat	VERB
dpc-4893	18	56	with	with	ADP
dpc-4893	18	57	bkz	bkz	PROPN
dpc-4893	18	58	(	(	PUNCT
dpc-4893	18	59	standard	standard	ADJ
dpc-4893	18	60	dosing	dose	VERB
dpc-4893	18	61	regimen	regiman	NOUN
dpc-4893	18	62	)	)	PUNCT
dpc-4893	18	63	were	be	AUX
dpc-4893	18	64	considered	consider	VERB
dpc-4893	18	65	;	;	PUNCT
dpc-4893	18	66	those	those	PRON
dpc-4893	18	67	lacking	lack	VERB
dpc-4893	18	68	24	24	NUM
dpc-4893	18	69	-	-	PUNCT
dpc-4893	18	70	week	week	NOUN
dpc-4893	18	71	follow	follow	NOUN
dpc-4893	18	72	-	-	PUNCT
dpc-4893	18	73	up	up	NOUN
dpc-4893	18	74	or	or	CCONJ
dpc-4893	18	75	on	on	ADP
dpc-4893	18	76	concomitant	concomitant	ADJ
dpc-4893	18	77	anti	anti	ADJ
dpc-4893	18	78	-	-	ADJ
dpc-4893	18	79	psoriatic	psoriatic	ADJ
dpc-4893	18	80	therapies	therapy	NOUN
dpc-4893	18	81	were	be	AUX
dpc-4893	18	82	excluded	exclude	VERB
dpc-4893	18	83	.	.	PUNCT
dpc-4893	19	1	demographic	demographic	ADJ
dpc-4893	19	2	and	and	CCONJ
dpc-4893	19	3	medical	medical	ADJ
dpc-4893	19	4	information	information	NOUN
dpc-4893	19	5	was	be	AUX
dpc-4893	19	6	collected	collect	VERB
dpc-4893	19	7	(	(	PUNCT
dpc-4893	19	8	gender	gender	NOUN
dpc-4893	19	9	,	,	PUNCT
dpc-4893	19	10	age	age	NOUN
dpc-4893	19	11	,	,	PUNCT
dpc-4893	19	12	bmi	bmi	NOUN
dpc-4893	19	13	,	,	PUNCT
dpc-4893	19	14	psoriasis	psoriasis	NOUN
dpc-4893	19	15	duration	duration	NOUN
dpc-4893	19	16	,	,	PUNCT
dpc-4893	19	17	comorbidities	comorbiditie	NOUN
dpc-4893	19	18	and	and	CCONJ
dpc-4893	19	19	previous	previous	ADJ
dpc-4893	19	20	/	/	SYM
dpc-4893	19	21	current	current	ADJ
dpc-4893	19	22	systemic	systemic	ADJ
dpc-4893	19	23	treatments	treatment	NOUN
dpc-4893	19	24	)	)	PUNCT
dpc-4893	19	25	.	.	PUNCT
dpc-4893	20	1	treatment	treatment	NOUN
dpc-4893	20	2	efficacy	efficacy	NOUN
dpc-4893	20	3	was	be	AUX
dpc-4893	20	4	evaluated	evaluate	VERB
dpc-4893	20	5	using	use	VERB
dpc-4893	20	6	pasi	pasi	NOUN
dpc-4893	20	7	score	score	NOUN
dpc-4893	20	8	at	at	ADP
dpc-4893	20	9	baseline	baseline	NOUN
dpc-4893	20	10	,	,	PUNCT
dpc-4893	20	11	week	week	NOUN
dpc-4893	20	12	4	4	NUM
dpc-4893	20	13	,	,	PUNCT
dpc-4893	20	14	week	week	NOUN
dpc-4893	20	15	16	16	NUM
dpc-4893	20	16	and	and	CCONJ
dpc-4893	20	17	week	week	NOUN
dpc-4893	20	18	24	24	NUM
dpc-4893	20	19	;	;	PUNCT
dpc-4893	20	20	percentage	percentage	NOUN
dpc-4893	20	21	improvement	improvement	NOUN
dpc-4893	20	22	compared	compare	VERB
dpc-4893	20	23	to	to	ADP
dpc-4893	20	24	baseline	baseline	VERB
dpc-4893	20	25	was	be	AUX
dpc-4893	20	26	also	also	ADV
dpc-4893	20	27	considered	consider	VERB
dpc-4893	20	28	(	(	PUNCT
dpc-4893	20	29	pasi75	pasi75	NOUN
dpc-4893	20	30	,	,	PUNCT
dpc-4893	20	31	90	90	NUM
dpc-4893	20	32	and	and	CCONJ
dpc-4893	20	33	100	100	NUM
dpc-4893	20	34	)	)	PUNCT
dpc-4893	20	35	at	at	ADP
dpc-4893	20	36	each	each	DET
dpc-4893	20	37	time	time	NOUN
dpc-4893	20	38	point	point	NOUN
dpc-4893	20	39	.	.	PUNCT
dpc-4893	21	1	safety	safety	NOUN
dpc-4893	21	2	profile	profile	NOUN
dpc-4893	21	3	was	be	AUX
dpc-4893	21	4	assessed	assess	VERB
dpc-4893	21	5	by	by	ADP
dpc-4893	21	6	monitoring	monitor	VERB
dpc-4893	21	7	incidence	incidence	NOUN
dpc-4893	21	8	and	and	CCONJ
dpc-4893	21	9	severity	severity	NOUN
dpc-4893	21	10	of	of	ADP
dpc-4893	21	11	adverse	adverse	ADJ
dpc-4893	21	12	events	event	NOUN
dpc-4893	21	13	(	(	PUNCT
dpc-4893	21	14	aes	aes	NOUN
dpc-4893	21	15	)	)	PUNCT
dpc-4893	21	16	.	.	PUNCT
dpc-4893	22	1	the	the	DET
dpc-4893	22	2	patients	patient	NOUN
dpc-4893	22	3	in	in	ADP
dpc-4893	22	4	this	this	DET
dpc-4893	22	5	manuscript	manuscript	NOUN
dpc-4893	22	6	provided	provide	VERB
dpc-4893	22	7	informed	informed	ADJ
dpc-4893	22	8	consent	consent	NOUN
dpc-4893	22	9	for	for	ADP
dpc-4893	22	10	the	the	DET
dpc-4893	22	11	publication	publication	NOUN
dpc-4893	22	12	of	of	ADP
dpc-4893	22	13	case	case	NOUN
dpc-4893	22	14	details	detail	NOUN
dpc-4893	22	15	,	,	PUNCT
dpc-4893	22	16	and	and	CCONJ
dpc-4893	22	17	institutional	institutional	ADJ
dpc-4893	22	18	approval	approval	NOUN
dpc-4893	22	19	was	be	AUX
dpc-4893	22	20	not	not	PART
dpc-4893	22	21	required	require	VERB
dpc-4893	22	22	,	,	PUNCT
dpc-4893	22	23	as	as	SCONJ
dpc-4893	22	24	the	the	DET
dpc-4893	22	25	study	study	NOUN
dpc-4893	22	26	was	be	AUX
dpc-4893	22	27	based	base	VERB
dpc-4893	22	28	vijayakumars	vijayakumar	NOUN
dpc-4893	22	29	sticky	sticky	ADJ
dpc-4893	22	30	note	note	NOUN
dpc-4893	22	31	marked	mark	VERB
dpc-4893	22	32	set	set	VERB
dpc-4893	22	33	by	by	ADP
dpc-4893	22	34	vijayakumars	vijayakumar	NOUN
dpc-4893	22	35	2	2	NUM
dpc-4893	22	36	research	research	NOUN
dpc-4893	22	37	letter	letter	NOUN
dpc-4893	23	1	|	|	ADV
dpc-4893	23	2	dermatol	dermatol	ADJ
dpc-4893	23	3	pract	pract	NOUN
dpc-4893	23	4	concept	concept	NOUN
dpc-4893	23	5	.	.	PUNCT
dpc-4893	24	1	2025;15(1):4893	2025;15(1):4893	NUM
dpc-4893	24	2	on	on	ADP
dpc-4893	24	3	data	datum	NOUN
dpc-4893	24	4	retrospectively	retrospectively	ADV
dpc-4893	24	5	collected	collect	VERB
dpc-4893	24	6	in	in	ADP
dpc-4893	24	7	a	a	DET
dpc-4893	24	8	routine	routine	ADJ
dpc-4893	24	9	clinical	clinical	ADJ
dpc-4893	24	10	setting	setting	NOUN
dpc-4893	24	11	.	.	PUNCT
dpc-4893	25	1	this	this	DET
dpc-4893	25	2	study	study	NOUN
dpc-4893	25	3	complies	comply	VERB
dpc-4893	25	4	with	with	ADP
dpc-4893	25	5	the	the	DET
dpc-4893	25	6	declaration	declaration	NOUN
dpc-4893	25	7	of	of	ADP
dpc-4893	25	8	helsinki	helsinki	PROPN
dpc-4893	25	9	and	and	CCONJ
dpc-4893	25	10	no	no	DET
dpc-4893	25	11	ethical	ethical	ADJ
dpc-4893	25	12	approval	approval	NOUN
dpc-4893	25	13	was	be	AUX
dpc-4893	25	14	required	require	VERB
dpc-4893	25	15	as	as	SCONJ
dpc-4893	25	16	it	it	PRON
dpc-4893	25	17	results	result	VERB
dpc-4893	25	18	from	from	ADP
dpc-4893	25	19	clinical	clinical	ADJ
dpc-4893	25	20	routinary	routinary	ADJ
dpc-4893	25	21	activity	activity	NOUN
dpc-4893	25	22	.	.	PUNCT
dpc-4893	26	1	a	a	DET
dpc-4893	26	2	total	total	NOUN
dpc-4893	26	3	of	of	ADP
dpc-4893	26	4	27	27	NUM
dpc-4893	26	5	obese	obese	ADJ
dpc-4893	26	6	patients	patient	NOUN
dpc-4893	26	7	with	with	ADP
dpc-4893	26	8	psoriasis	psoriasis	NOUN
dpc-4893	26	9	met	meet	VERB
dpc-4893	26	10	our	our	PRON
dpc-4893	26	11	inclusion	inclusion	NOUN
dpc-4893	26	12	criteria	criterion	NOUN
dpc-4893	26	13	,	,	PUNCT
dpc-4893	26	14	with	with	ADP
dpc-4893	26	15	a	a	DET
dpc-4893	26	16	mean	mean	ADJ
dpc-4893	26	17	age	age	NOUN
dpc-4893	26	18	of	of	ADP
dpc-4893	26	19	50.0	50.0	NUM
dpc-4893	26	20	±	±	NUM
dpc-4893	26	21	12.1	12.1	NUM
dpc-4893	26	22	years	year	NOUN
dpc-4893	26	23	and	and	CCONJ
dpc-4893	26	24	mean	mean	VERB
dpc-4893	26	25	bmi	bmi	NOUN
dpc-4893	26	26	of	of	ADP
dpc-4893	26	27	33.4	33.4	NUM
dpc-4893	26	28	±	±	NUM
dpc-4893	26	29	3.6	3.6	NUM
dpc-4893	26	30	kg	kg	NOUN
dpc-4893	26	31	/	/	SYM
dpc-4893	26	32	m2	m2	PROPN
dpc-4893	26	33	.	.	PUNCT
dpc-4893	27	1	the	the	DET
dpc-4893	27	2	mean	mean	ADJ
dpc-4893	27	3	duration	duration	NOUN
dpc-4893	27	4	of	of	ADP
dpc-4893	27	5	psoriasis	psoriasis	NOUN
dpc-4893	27	6	was	be	AUX
dpc-4893	27	7	16.9	16.9	NUM
dpc-4893	27	8	±	±	NUM
dpc-4893	27	9	8.8	8.8	NUM
dpc-4893	27	10	years	year	NOUN
dpc-4893	27	11	.	.	PUNCT
dpc-4893	28	1	at	at	ADP
dpc-4893	28	2	baseline	baseline	NOUN
dpc-4893	28	3	,	,	PUNCT
dpc-4893	28	4	the	the	DET
dpc-4893	28	5	mean	mean	ADJ
dpc-4893	28	6	pasi	pasi	NOUN
dpc-4893	28	7	was	be	AUX
dpc-4893	28	8	13.3	13.3	NUM
dpc-4893	28	9	±	±	NUM
dpc-4893	28	10	8.2	8.2	NUM
dpc-4893	28	11	,	,	PUNCT
dpc-4893	28	12	with	with	ADP
dpc-4893	28	13	74.1	74.1	NUM
dpc-4893	28	14	%	%	NOUN
dpc-4893	28	15	of	of	ADP
dpc-4893	28	16	patients	patient	NOUN
dpc-4893	28	17	having	have	VERB
dpc-4893	28	18	at	at	ADV
dpc-4893	28	19	least	least	ADV
dpc-4893	28	20	1	1	NUM
dpc-4893	28	21	difficult	difficult	ADJ
dpc-4893	28	22	to	to	PART
dpc-4893	28	23	-	-	PUNCT
dpc-4893	28	24	treat	treat	VERB
dpc-4893	28	25	area	area	NOUN
dpc-4893	28	26	affected	affect	VERB
dpc-4893	28	27	(	(	PUNCT
dpc-4893	28	28	genitalia	genitalia	NOUN
dpc-4893	28	29	,	,	PUNCT
dpc-4893	28	30	scalp	scalp	NOUN
dpc-4893	28	31	,	,	PUNCT
dpc-4893	28	32	palms	palm	NOUN
dpc-4893	28	33	/	/	SYM
dpc-4893	28	34	soles	sol	NOUN
dpc-4893	28	35	)	)	PUNCT
dpc-4893	28	36	,	,	PUNCT
dpc-4893	28	37	and	and	CCONJ
dpc-4893	28	38	40.7	40.7	NUM
dpc-4893	28	39	%	%	NOUN
dpc-4893	28	40	with	with	ADP
dpc-4893	28	41	nail	nail	NOUN
dpc-4893	28	42	involvement	involvement	NOUN
dpc-4893	28	43	.	.	PUNCT
dpc-4893	29	1	most	most	ADJ
dpc-4893	29	2	patients	patient	NOUN
dpc-4893	29	3	(	(	PUNCT
dpc-4893	29	4	81.5	81.5	NUM
dpc-4893	29	5	%	%	NOUN
dpc-4893	29	6	)	)	PUNCT
dpc-4893	29	7	had	have	AUX
dpc-4893	29	8	been	be	AUX
dpc-4893	29	9	previously	previously	ADV
dpc-4893	29	10	treated	treat	VERB
dpc-4893	29	11	with	with	ADP
dpc-4893	29	12	at	at	ADV
dpc-4893	29	13	least	least	ADV
dpc-4893	29	14	1	1	NUM
dpc-4893	29	15	conventional	conventional	ADJ
dpc-4893	29	16	therapy	therapy	NOUN
dpc-4893	29	17	,	,	PUNCT
dpc-4893	29	18	and	and	CCONJ
dpc-4893	29	19	66.7	66.7	NUM
dpc-4893	29	20	%	%	NOUN
dpc-4893	29	21	had	have	AUX
dpc-4893	29	22	received	receive	VERB
dpc-4893	29	23	at	at	ADV
dpc-4893	29	24	least	least	ADJ
dpc-4893	29	25	1	1	NUM
dpc-4893	29	26	biologic	biologic	NOUN
dpc-4893	29	27	therapy	therapy	NOUN
dpc-4893	29	28	.	.	PUNCT
dpc-4893	30	1	the	the	DET
dpc-4893	30	2	most	most	ADV
dpc-4893	30	3	common	common	ADJ
dpc-4893	30	4	comorbidity	comorbidity	NOUN
dpc-4893	30	5	was	be	AUX
dpc-4893	30	6	arterial	arterial	ADJ
dpc-4893	30	7	hypertension	hypertension	NOUN
dpc-4893	30	8	(	(	PUNCT
dpc-4893	30	9	40.7	40.7	NUM
dpc-4893	30	10	%	%	NOUN
dpc-4893	30	11	)	)	PUNCT
dpc-4893	30	12	.	.	PUNCT
dpc-4893	31	1	all	all	PRON
dpc-4893	31	2	baseline	baseline	VERB
dpc-4893	31	3	demographic	demographic	ADJ
dpc-4893	31	4	and	and	CCONJ
dpc-4893	31	5	clinical	clinical	ADJ
dpc-4893	31	6	data	datum	NOUN
dpc-4893	31	7	of	of	ADP
dpc-4893	31	8	included	include	VERB
dpc-4893	31	9	patients	patient	NOUN
dpc-4893	31	10	are	be	AUX
dpc-4893	31	11	summarized	summarize	VERB
dpc-4893	31	12	in	in	ADP
dpc-4893	31	13	table	table	NOUN
dpc-4893	31	14	1	1	NUM
dpc-4893	31	15	.	.	PUNCT
dpc-4893	32	1	during	during	ADP
dpc-4893	32	2	the	the	DET
dpc-4893	32	3	follow	follow	NOUN
dpc-4893	32	4	-	-	PUNCT
dpc-4893	32	5	up	up	NOUN
dpc-4893	32	6	,	,	PUNCT
dpc-4893	32	7	the	the	DET
dpc-4893	32	8	mean	mean	ADJ
dpc-4893	32	9	pasi	pasi	NOUN
dpc-4893	32	10	score	score	NOUN
dpc-4893	32	11	decreased	decrease	VERB
dpc-4893	32	12	from	from	ADP
dpc-4893	32	13	13.3	13.3	NUM
dpc-4893	32	14	±	±	NUM
dpc-4893	32	15	8.1	8.1	NUM
dpc-4893	32	16	at	at	ADP
dpc-4893	32	17	baseline	baseline	NOUN
dpc-4893	32	18	to	to	ADP
dpc-4893	32	19	2.3	2.3	NUM
dpc-4893	32	20	±	±	NUM
dpc-4893	32	21	2.4	2.4	NUM
dpc-4893	32	22	at	at	ADP
dpc-4893	32	23	week	week	NOUN
dpc-4893	32	24	4	4	NUM
dpc-4893	32	25	,	,	PUNCT
dpc-4893	32	26	1.0	1.0	NUM
dpc-4893	32	27	±	±	NUM
dpc-4893	32	28	1.7	1.7	NUM
dpc-4893	32	29	at	at	ADP
dpc-4893	32	30	week	week	NOUN
dpc-4893	32	31	16	16	NUM
dpc-4893	32	32	,	,	PUNCT
dpc-4893	32	33	and	and	CCONJ
dpc-4893	32	34	0.6	0.6	NUM
dpc-4893	32	35	±	±	NUM
dpc-4893	32	36	1.5	1.5	NUM
dpc-4893	32	37	at	at	ADP
dpc-4893	32	38	week	week	NOUN
dpc-4893	32	39	24	24	NUM
dpc-4893	32	40	(	(	PUNCT
dpc-4893	32	41	figure	figure	NOUN
dpc-4893	32	42	1	1	NUM
dpc-4893	32	43	)	)	PUNCT
dpc-4893	32	44	.	.	PUNCT
dpc-4893	33	1	the	the	DET
dpc-4893	33	2	percentage	percentage	NOUN
dpc-4893	33	3	of	of	ADP
dpc-4893	33	4	patients	patient	NOUN
dpc-4893	33	5	achieving	achieve	VERB
dpc-4893	33	6	pasi75	pasi75	NOUN
dpc-4893	33	7	,	,	PUNCT
dpc-4893	33	8	pasi90	pasi90	NOUN
dpc-4893	33	9	,	,	PUNCT
dpc-4893	33	10	and	and	CCONJ
dpc-4893	33	11	pasi100	pasi100	PROPN
dpc-4893	33	12	improved	improve	VERB
dpc-4893	33	13	steadily	steadily	ADV
dpc-4893	33	14	over	over	ADP
dpc-4893	33	15	the	the	DET
dpc-4893	33	16	study	study	NOUN
dpc-4893	33	17	period	period	NOUN
dpc-4893	33	18	:	:	PUNCT
dpc-4893	33	19	week	week	NOUN
dpc-4893	33	20	4	4	NUM
dpc-4893	33	21	:	:	PUNCT
dpc-4893	33	22	pasi75	pasi75	NOUN
dpc-4893	33	23	(	(	PUNCT
dpc-4893	33	24	74.1	74.1	NUM
dpc-4893	33	25	%	%	NOUN
dpc-4893	33	26	)	)	PUNCT
dpc-4893	33	27	,	,	PUNCT
dpc-4893	33	28	pasi90	pasi90	NOUN
dpc-4893	33	29	(	(	PUNCT
dpc-4893	33	30	37.0	37.0	NUM
dpc-4893	33	31	%	%	NOUN
dpc-4893	33	32	)	)	PUNCT
dpc-4893	33	33	,	,	PUNCT
dpc-4893	33	34	pasi100	pasi100	PROPN
dpc-4893	33	35	(	(	PUNCT
dpc-4893	33	36	25.9	25.9	NUM
dpc-4893	33	37	%	%	NOUN
dpc-4893	33	38	)	)	PUNCT
dpc-4893	33	39	;	;	PUNCT
dpc-4893	33	40	week	week	NOUN
dpc-4893	33	41	16	16	NUM
dpc-4893	33	42	:	:	PUNCT
dpc-4893	33	43	pasi75	pasi75	NOUN
dpc-4893	33	44	(	(	PUNCT
dpc-4893	33	45	88.9	88.9	NUM
dpc-4893	33	46	%	%	NOUN
dpc-4893	33	47	)	)	PUNCT
dpc-4893	33	48	,	,	PUNCT
dpc-4893	33	49	pasi90	pasi90	NOUN
dpc-4893	33	50	(	(	PUNCT
dpc-4893	33	51	70.4	70.4	NUM
dpc-4893	33	52	%	%	NOUN
dpc-4893	33	53	)	)	PUNCT
dpc-4893	33	54	,	,	PUNCT
dpc-4893	33	55	pasi100	pasi100	PROPN
dpc-4893	33	56	(	(	PUNCT
dpc-4893	33	57	55.6	55.6	NUM
dpc-4893	33	58	%	%	NOUN
dpc-4893	33	59	)	)	PUNCT
dpc-4893	33	60	;	;	PUNCT
dpc-4893	33	61	and	and	CCONJ
dpc-4893	33	62	week	week	NOUN
dpc-4893	33	63	24	24	NUM
dpc-4893	33	64	:	:	PUNCT
dpc-4893	33	65	pasi75	pasi75	NOUN
dpc-4893	33	66	(	(	PUNCT
dpc-4893	33	67	96.3	96.3	NUM
dpc-4893	33	68	%	%	NOUN
dpc-4893	33	69	)	)	PUNCT
dpc-4893	33	70	,	,	PUNCT
dpc-4893	33	71	pasi90	pasi90	NOUN
dpc-4893	33	72	(	(	PUNCT
dpc-4893	33	73	85.2	85.2	NUM
dpc-4893	33	74	%	%	NOUN
dpc-4893	33	75	)	)	PUNCT
dpc-4893	33	76	,	,	PUNCT
dpc-4893	33	77	pasi100	pasi100	PROPN
dpc-4893	33	78	(	(	PUNCT
dpc-4893	33	79	74.1	74.1	NUM
dpc-4893	33	80	%	%	NOUN
dpc-4893	33	81	)	)	PUNCT
dpc-4893	33	82	.	.	PUNCT
dpc-4893	34	1	bkz	bkz	PROPN
dpc-4893	34	2	was	be	AUX
dpc-4893	34	3	generally	generally	ADV
dpc-4893	34	4	well	well	ADV
dpc-4893	34	5	tolerated	tolerate	VERB
dpc-4893	34	6	,	,	PUNCT
dpc-4893	34	7	with	with	ADP
dpc-4893	34	8	only	only	ADV
dpc-4893	34	9	1	1	NUM
dpc-4893	34	10	patient	patient	NOUN
dpc-4893	34	11	(	(	PUNCT
dpc-4893	34	12	3.7	3.7	NUM
dpc-4893	34	13	%	%	NOUN
dpc-4893	34	14	)	)	PUNCT
dpc-4893	34	15	discontinuing	discontinue	VERB
dpc-4893	34	16	treatment	treatment	NOUN
dpc-4893	34	17	at	at	ADP
dpc-4893	34	18	week	week	NOUN
dpc-4893	34	19	12	12	NUM
dpc-4893	34	20	due	due	ADP
dpc-4893	34	21	to	to	ADP
dpc-4893	34	22	axillary	axillary	ADJ
dpc-4893	34	23	candidiasis	candidiasis	NOUN
dpc-4893	34	24	and	and	CCONJ
dpc-4893	34	25	urinary	urinary	ADJ
dpc-4893	34	26	tract	tract	NOUN
dpc-4893	34	27	infection	infection	NOUN
dpc-4893	34	28	,	,	PUNCT
dpc-4893	34	29	which	which	PRON
dpc-4893	34	30	were	be	AUX
dpc-4893	34	31	treated	treat	VERB
dpc-4893	34	32	successfully	successfully	ADV
dpc-4893	34	33	,	,	PUNCT
dpc-4893	34	34	allowing	allow	VERB
dpc-4893	34	35	bkz	bkz	VERB
dpc-4893	34	36	treatment	treatment	NOUN
dpc-4893	34	37	to	to	PART
dpc-4893	34	38	resume	resume	VERB
dpc-4893	34	39	without	without	ADP
dpc-4893	34	40	further	further	ADJ
dpc-4893	34	41	adverse	adverse	ADJ
dpc-4893	34	42	events	event	NOUN
dpc-4893	34	43	(	(	PUNCT
dpc-4893	34	44	aes	aes	PROPN
dpc-4893	34	45	)	)	PUNCT
dpc-4893	34	46	;	;	PUNCT
dpc-4893	34	47	no	no	DET
dpc-4893	34	48	other	other	ADJ
dpc-4893	34	49	significant	significant	ADJ
dpc-4893	34	50	aes	aes	NOUN
dpc-4893	34	51	were	be	AUX
dpc-4893	34	52	reported	report	VERB
dpc-4893	34	53	.	.	PUNCT
dpc-4893	35	1	conclusions	conclusion	NOUN
dpc-4893	35	2	in	in	ADP
dpc-4893	35	3	conclusion	conclusion	NOUN
dpc-4893	35	4	,	,	PUNCT
dpc-4893	35	5	this	this	DET
dpc-4893	35	6	24	24	NUM
dpc-4893	35	7	-	-	PUNCT
dpc-4893	35	8	week	week	NOUN
dpc-4893	35	9	real	real	ADJ
dpc-4893	35	10	-	-	PUNCT
dpc-4893	35	11	life	life	NOUN
dpc-4893	35	12	study	study	NOUN
dpc-4893	35	13	indicates	indicate	VERB
dpc-4893	35	14	that	that	SCONJ
dpc-4893	35	15	bkz	bkz	NOUN
dpc-4893	35	16	is	be	AUX
dpc-4893	35	17	an	an	DET
dpc-4893	35	18	effective	effective	ADJ
dpc-4893	35	19	treatment	treatment	NOUN
dpc-4893	35	20	for	for	ADP
dpc-4893	35	21	moderate	moderate	ADJ
dpc-4893	35	22	-	-	PUNCT
dpc-4893	35	23	to	to	ADP
dpc-4893	35	24	-	-	PUNCT
dpc-4893	35	25	severe/	severe/	NOUN
dpc-4893	35	26	difficult	difficult	ADJ
dpc-4893	35	27	-	-	PUNCT
dpc-4893	35	28	to	to	AUX
dpc-4893	35	29	-	-	PUNCT
dpc-4893	35	30	treat	treat	VERB
dpc-4893	35	31	plaque	plaque	NOUN
dpc-4893	35	32	-	-	PUNCT
dpc-4893	35	33	type	type	NOUN
dpc-4893	35	34	psoriasis	psoriasis	NOUN
dpc-4893	35	35	in	in	ADP
dpc-4893	35	36	obese	obese	ADJ
dpc-4893	35	37	patients	patient	NOUN
dpc-4893	35	38	.	.	PUNCT
dpc-4893	36	1	the	the	DET
dpc-4893	36	2	treatment	treatment	NOUN
dpc-4893	36	3	resulted	result	VERB
dpc-4893	36	4	in	in	ADP
dpc-4893	36	5	substantial	substantial	ADJ
dpc-4893	36	6	pasi	pasi	NOUN
dpc-4893	36	7	improvements	improvement	NOUN
dpc-4893	36	8	,	,	PUNCT
dpc-4893	36	9	with	with	ADP
dpc-4893	36	10	20	20	NUM
dpc-4893	36	11	and	and	CCONJ
dpc-4893	36	12	23	23	NUM
dpc-4893	36	13	patients	patient	NOUN
dpc-4893	36	14	respectively	respectively	ADV
dpc-4893	36	15	achieving	achieve	VERB
dpc-4893	36	16	complete	complete	ADJ
dpc-4893	36	17	and	and	CCONJ
dpc-4893	36	18	nearly	nearly	ADV
dpc-4893	36	19	complete	complete	ADJ
dpc-4893	36	20	responses	response	NOUN
dpc-4893	36	21	(	(	PUNCT
dpc-4893	36	22	described	describe	VERB
dpc-4893	36	23	as	as	ADP
dpc-4893	36	24	pasi100	pasi100	PROPN
dpc-4893	36	25	and	and	CCONJ
dpc-4893	36	26	pasi90	pasi90	NOUN
dpc-4893	36	27	respectively	respectively	ADV
dpc-4893	36	28	)	)	PUNCT
dpc-4893	36	29	.	.	PUNCT
dpc-4893	37	1	bkz	bkz	VERB
dpc-4893	37	2	efficacy	efficacy	NOUN
dpc-4893	37	3	in	in	ADP
dpc-4893	37	4	this	this	DET
dpc-4893	37	5	cohort	cohort	NOUN
dpc-4893	37	6	was	be	AUX
dpc-4893	37	7	greater	great	ADJ
dpc-4893	37	8	than	than	ADP
dpc-4893	37	9	both	both	CCONJ
dpc-4893	37	10	anti	anti	ADJ
dpc-4893	37	11	-	-	ADJ
dpc-4893	37	12	il-17	il-17	ADV
dpc-4893	37	13	secukinumab	secukinumab	NOUN
dpc-4893	37	14	(	(	PUNCT
dpc-4893	37	15	which	which	PRON
dpc-4893	37	16	yielded	yield	VERB
dpc-4893	37	17	a	a	DET
dpc-4893	37	18	worse	bad	ADJ
dpc-4893	37	19	mean	mean	NOUN
dpc-4893	37	20	pasi	pasi	NOUN
dpc-4893	37	21	decrease	decrease	NOUN
dpc-4893	37	22	from	from	ADP
dpc-4893	37	23	baseline	baseline	NOUN
dpc-4893	37	24	to	to	ADP
dpc-4893	37	25	week	week	NOUN
dpc-4893	37	26	24	24	NUM
dpc-4893	37	27	)	)	PUNCT
dpc-4893	37	28	and	and	CCONJ
dpc-4893	37	29	brodalumab	brodalumab	NOUN
dpc-4893	37	30	(	(	PUNCT
dpc-4893	37	31	week	week	NOUN
dpc-4893	37	32	24	24	NUM
dpc-4893	37	33	pasi75	pasi75	NOUN
dpc-4893	37	34	,	,	PUNCT
dpc-4893	37	35	pasi90	pasi90	NOUN
dpc-4893	37	36	,	,	PUNCT
dpc-4893	37	37	pasi100	pasi100	PROPN
dpc-4893	37	38	of	of	ADP
dpc-4893	37	39	88.07	88.07	NUM
dpc-4893	37	40	%	%	NOUN
dpc-4893	37	41	,	,	PUNCT
dpc-4893	37	42	74.31	74.31	NUM
dpc-4893	37	43	%	%	NOUN
dpc-4893	37	44	and	and	CCONJ
dpc-4893	37	45	53.32	53.32	NUM
dpc-4893	37	46	%	%	NOUN
dpc-4893	37	47	respectively	respectively	ADV
dpc-4893	37	48	)	)	PUNCT
dpc-4893	37	49	and	and	CCONJ
dpc-4893	37	50	anti	anti	ADJ
dpc-4893	37	51	-	-	ADJ
dpc-4893	37	52	il-23	il-23	ADJ
dpc-4893	37	53	agents	agent	NOUN
dpc-4893	37	54	guselkumab	guselkumab	NOUN
dpc-4893	37	55	(	(	PUNCT
dpc-4893	37	56	week	week	NOUN
dpc-4893	37	57	24	24	NUM
dpc-4893	37	58	pasi75	pasi75	NOUN
dpc-4893	37	59	,	,	PUNCT
dpc-4893	37	60	pasi90	pasi90	NOUN
dpc-4893	37	61	,	,	PUNCT
dpc-4893	37	62	pasi100	pasi100	PROPN
dpc-4893	37	63	of	of	ADP
dpc-4893	37	64	89.5	89.5	NUM
dpc-4893	37	65	%	%	NOUN
dpc-4893	37	66	,	,	PUNCT
dpc-4893	37	67	73.3	73.3	NUM
dpc-4893	37	68	%	%	NOUN
dpc-4893	37	69	and	and	CCONJ
dpc-4893	37	70	50	50	NUM
dpc-4893	37	71	%	%	NOUN
dpc-4893	37	72	respectively	respectively	ADV
dpc-4893	37	73	)	)	PUNCT
dpc-4893	37	74	and	and	CCONJ
dpc-4893	37	75	risankizumab	risankizumab	NOUN
dpc-4893	37	76	(	(	PUNCT
dpc-4893	37	77	week	week	NOUN
dpc-4893	37	78	16	16	NUM
dpc-4893	37	79	pasi75	pasi75	NOUN
dpc-4893	37	80	,	,	PUNCT
dpc-4893	37	81	pasi90	pasi90	NOUN
dpc-4893	37	82	,	,	PUNCT
dpc-4893	37	83	pasi100	pasi100	PROPN
dpc-4893	37	84	of	of	ADP
dpc-4893	37	85	66	66	NUM
dpc-4893	37	86	%	%	NOUN
dpc-4893	37	87	,	,	PUNCT
dpc-4893	37	88	40	40	NUM
dpc-4893	37	89	%	%	NOUN
dpc-4893	37	90	,	,	PUNCT
dpc-4893	37	91	28	28	NUM
dpc-4893	37	92	%	%	NOUN
dpc-4893	37	93	respectively	respectively	ADV
dpc-4893	37	94	and	and	CCONJ
dpc-4893	37	95	week	week	NOUN
dpc-4893	37	96	28	28	NUM
dpc-4893	37	97	pasi75	pasi75	NOUN
dpc-4893	37	98	,	,	PUNCT
dpc-4893	37	99	pasi90	pasi90	NOUN
dpc-4893	37	100	,	,	PUNCT
dpc-4893	37	101	pasi100	pasi100	PROPN
dpc-4893	37	102	of	of	ADP
dpc-4893	37	103	87	87	NUM
dpc-4893	37	104	%	%	NOUN
dpc-4893	37	105	,	,	PUNCT
dpc-4893	37	106	72	72	NUM
dpc-4893	37	107	%	%	NOUN
dpc-4893	37	108	,	,	PUNCT
dpc-4893	37	109	58	58	NUM
dpc-4893	37	110	%	%	NOUN
dpc-4893	37	111	respectively	respectively	ADV
dpc-4893	37	112	)	)	PUNCT
dpc-4893	37	113	in	in	ADP
dpc-4893	37	114	the	the	DET
dpc-4893	37	115	same	same	ADJ
dpc-4893	37	116	subset	subset	NOUN
dpc-4893	37	117	of	of	ADP
dpc-4893	37	118	patients	patient	NOUN
dpc-4893	37	119	in	in	ADP
dpc-4893	37	120	real	real	ADJ
dpc-4893	37	121	life	life	NOUN
dpc-4893	37	122	[	[	X
dpc-4893	37	123	1	1	NUM
dpc-4893	37	124	-	-	SYM
dpc-4893	37	125	4	4	NUM
dpc-4893	37	126	]	]	PUNCT
dpc-4893	37	127	.	.	PUNCT
dpc-4893	38	1	despite	despite	SCONJ
dpc-4893	38	2	multiple	multiple	ADJ
dpc-4893	38	3	comorbidities	comorbiditie	NOUN
dpc-4893	38	4	typical	typical	ADJ
dpc-4893	38	5	of	of	ADP
dpc-4893	38	6	obese	obese	ADJ
dpc-4893	38	7	populations	population	NOUN
dpc-4893	38	8	,	,	PUNCT
dpc-4893	38	9	bkz	bkz	VERB
dpc-4893	38	10	demonstrated	demonstrate	VERB
dpc-4893	38	11	a	a	DET
dpc-4893	38	12	favorable	favorable	ADJ
dpc-4893	38	13	safety	safety	NOUN
dpc-4893	38	14	profile	profile	NOUN
dpc-4893	38	15	.	.	PUNCT
dpc-4893	39	1	these	these	DET
dpc-4893	39	2	findings	finding	NOUN
dpc-4893	39	3	suggest	suggest	VERB
dpc-4893	39	4	that	that	SCONJ
dpc-4893	39	5	bkz	bkz	NOUN
dpc-4893	39	6	could	could	AUX
dpc-4893	39	7	be	be	AUX
dpc-4893	39	8	considered	consider	VERB
dpc-4893	39	9	as	as	ADP
dpc-4893	39	10	an	an	DET
dpc-4893	39	11	optimal	optimal	ADJ
dpc-4893	39	12	biologic	biologic	NOUN
dpc-4893	39	13	table	table	NOUN
dpc-4893	39	14	1	1	NUM
dpc-4893	39	15	.	.	PUNCT
dpc-4893	39	16	demographic	demographic	ADJ
dpc-4893	39	17	and	and	CCONJ
dpc-4893	39	18	clinical	clinical	ADJ
dpc-4893	39	19	data	datum	NOUN
dpc-4893	39	20	of	of	ADP
dpc-4893	39	21	study	study	NOUN
dpc-4893	39	22	population	population	NOUN
dpc-4893	39	23	*	*	PUNCT
dpc-4893	39	24	study	study	NOUN
dpc-4893	39	25	population	population	NOUN
dpc-4893	39	26	patients	patient	NOUN
dpc-4893	39	27	,	,	PUNCT
dpc-4893	39	28	n	n	PRON
dpc-4893	39	29	27	27	NUM
dpc-4893	39	30	age	age	NOUN
dpc-4893	39	31	,	,	PUNCT
dpc-4893	39	32	years	year	NOUN
dpc-4893	39	33	50.0	50.0	NUM
dpc-4893	39	34	±	±	NUM
dpc-4893	39	35	12.1	12.1	NUM
dpc-4893	39	36	sex	sex	NOUN
dpc-4893	39	37	,	,	PUNCT
dpc-4893	39	38	male	male	NOUN
dpc-4893	39	39	19	19	NUM
dpc-4893	39	40	(	(	PUNCT
dpc-4893	39	41	70.4	70.4	NUM
dpc-4893	39	42	%	%	NOUN
dpc-4893	39	43	)	)	PUNCT
dpc-4893	39	44	body	body	NOUN
dpc-4893	39	45	mass	mass	PROPN
dpc-4893	39	46	index	index	NOUN
dpc-4893	39	47	,	,	PUNCT
dpc-4893	39	48	kg	kg	PROPN
dpc-4893	39	49	/	/	SYM
dpc-4893	39	50	m2	m2	PROPN
dpc-4893	39	51	33.4	33.4	NUM
dpc-4893	39	52	±	±	NUM
dpc-4893	39	53	3.6	3.6	NUM
dpc-4893	39	54	psoriasis	psoriasis	NOUN
dpc-4893	39	55	duration	duration	NOUN
dpc-4893	39	56	,	,	PUNCT
dpc-4893	39	57	years	year	NOUN
dpc-4893	39	58	16.9	16.9	NUM
dpc-4893	39	59	±	±	NUM
dpc-4893	39	60	8.8	8.8	NUM
dpc-4893	39	61	psoriasis	psoriasis	NOUN
dpc-4893	39	62	family	family	NOUN
dpc-4893	39	63	history	history	NOUN
dpc-4893	39	64	,	,	PUNCT
dpc-4893	39	65	n	n	CCONJ
dpc-4893	39	66	(	(	PUNCT
dpc-4893	39	67	%	%	INTJ
dpc-4893	39	68	)	)	PUNCT
dpc-4893	39	69	10	10	NUM
dpc-4893	39	70	(	(	PUNCT
dpc-4893	39	71	37.0	37.0	NUM
dpc-4893	39	72	%	%	NOUN
dpc-4893	39	73	)	)	PUNCT
dpc-4893	39	74	psoriatic	psoriatic	ADJ
dpc-4893	39	75	arthritis	arthritis	NOUN
dpc-4893	39	76	,	,	PUNCT
dpc-4893	39	77	n	n	PROPN
dpc-4893	39	78	(	(	PUNCT
dpc-4893	39	79	%	%	INTJ
dpc-4893	39	80	)	)	PUNCT
dpc-4893	39	81	5	5	NUM
dpc-4893	39	82	(	(	PUNCT
dpc-4893	39	83	18.5	18.5	NUM
dpc-4893	39	84	%	%	NOUN
dpc-4893	39	85	)	)	PUNCT
dpc-4893	39	86	psoriatic	psoriatic	ADJ
dpc-4893	39	87	arthritis	arthritis	NOUN
dpc-4893	39	88	duration	duration	NOUN
dpc-4893	39	89	,	,	PUNCT
dpc-4893	39	90	years	year	NOUN
dpc-4893	39	91	5.2	5.2	NUM
dpc-4893	39	92	±	±	NUM
dpc-4893	39	93	4.2	4.2	NUM
dpc-4893	39	94	involvement	involvement	NOUN
dpc-4893	39	95	of	of	ADP
dpc-4893	39	96	difficult	difficult	ADJ
dpc-4893	39	97	to	to	PART
dpc-4893	39	98	treat	treat	VERB
dpc-4893	39	99	areas	area	NOUN
dpc-4893	39	100	,	,	PUNCT
dpc-4893	39	101	n	n	CCONJ
dpc-4893	39	102	(	(	PUNCT
dpc-4893	39	103	%	%	INTJ
dpc-4893	39	104	)	)	PUNCT
dpc-4893	39	105	scalp	scalp	NOUN
dpc-4893	39	106	genitals	genital	NOUN
dpc-4893	39	107	palms	palm	NOUN
dpc-4893	39	108	and	and	CCONJ
dpc-4893	39	109	soles	sol	NOUN
dpc-4893	39	110	20	20	NUM
dpc-4893	39	111	(	(	PUNCT
dpc-4893	39	112	74.1	74.1	NUM
dpc-4893	39	113	%	%	NOUN
dpc-4893	39	114	)	)	PUNCT
dpc-4893	39	115	12	12	NUM
dpc-4893	39	116	(	(	PUNCT
dpc-4893	39	117	44.4	44.4	NUM
dpc-4893	39	118	%	%	NOUN
dpc-4893	39	119	)	)	PUNCT
dpc-4893	39	120	13	13	NUM
dpc-4893	39	121	(	(	PUNCT
dpc-4893	39	122	48.1	48.1	NUM
dpc-4893	39	123	%	%	NOUN
dpc-4893	39	124	)	)	PUNCT
dpc-4893	39	125	4	4	NUM
dpc-4893	39	126	(	(	PUNCT
dpc-4893	39	127	14.8	14.8	NUM
dpc-4893	39	128	%	%	NOUN
dpc-4893	39	129	)	)	PUNCT
dpc-4893	39	130	nail	nail	NOUN
dpc-4893	39	131	involvement	involvement	NOUN
dpc-4893	39	132	,	,	PUNCT
dpc-4893	39	133	n	n	CCONJ
dpc-4893	39	134	(	(	PUNCT
dpc-4893	39	135	%	%	INTJ
dpc-4893	39	136	)	)	PUNCT
dpc-4893	39	137	11	11	NUM
dpc-4893	39	138	(	(	PUNCT
dpc-4893	39	139	40.7	40.7	NUM
dpc-4893	39	140	%	%	NOUN
dpc-4893	39	141	)	)	PUNCT
dpc-4893	39	142	pasi	pasi	PROPN
dpc-4893	39	143	baseline	baseline	PROPN
dpc-4893	39	144	w4	w4	PROPN
dpc-4893	39	145	w16	w16	PROPN
dpc-4893	39	146	w24	w24	PROPN
dpc-4893	39	147	13.3	13.3	NUM
dpc-4893	39	148	±	±	NUM
dpc-4893	39	149	8.2	8.2	NUM
dpc-4893	39	150	2.3	2.3	NUM
dpc-4893	39	151	±	±	NUM
dpc-4893	39	152	2.4	2.4	NUM
dpc-4893	39	153	1.0	1.0	NUM
dpc-4893	39	154	±	±	NUM
dpc-4893	39	155	1.7	1.7	NUM
dpc-4893	39	156	0.6	0.6	NUM
dpc-4893	39	157	±	±	NUM
dpc-4893	39	158	1.5	1.5	NUM
dpc-4893	39	159	comorbidities	comorbiditie	NOUN
dpc-4893	39	160	or	or	CCONJ
dpc-4893	39	161	associated	associated	ADJ
dpc-4893	39	162	disease	disease	NOUN
dpc-4893	39	163	,	,	PUNCT
dpc-4893	39	164	n	n	CCONJ
dpc-4893	39	165	(	(	PUNCT
dpc-4893	39	166	%	%	INTJ
dpc-4893	39	167	):	):	PUNCT
dpc-4893	39	168	hypertension	hypertension	NOUN
dpc-4893	39	169	diabetes	diabetes	NOUN
dpc-4893	39	170	hyperuricemia	hyperuricemia	NOUN
dpc-4893	39	171	chronic	chronic	ADJ
dpc-4893	39	172	kidney	kidney	NOUN
dpc-4893	39	173	disease	disease	NOUN
dpc-4893	39	174	11	11	NUM
dpc-4893	39	175	(	(	PUNCT
dpc-4893	39	176	40.7	40.7	NUM
dpc-4893	39	177	%	%	NOUN
dpc-4893	39	178	)	)	PUNCT
dpc-4893	39	179	9	9	NUM
dpc-4893	39	180	(	(	PUNCT
dpc-4893	39	181	33.3	33.3	NUM
dpc-4893	39	182	%	%	NOUN
dpc-4893	39	183	)	)	PUNCT
dpc-4893	39	184	4	4	NUM
dpc-4893	39	185	(	(	PUNCT
dpc-4893	39	186	14.8	14.8	NUM
dpc-4893	39	187	%	%	NOUN
dpc-4893	39	188	)	)	PUNCT
dpc-4893	39	189	2	2	NUM
dpc-4893	39	190	(	(	PUNCT
dpc-4893	39	191	7.4	7.4	NUM
dpc-4893	39	192	%	%	NOUN
dpc-4893	39	193	)	)	PUNCT
dpc-4893	39	194	previous	previous	ADJ
dpc-4893	39	195	conventional	conventional	ADJ
dpc-4893	39	196	treatments	treatment	NOUN
dpc-4893	39	197	,	,	PUNCT
dpc-4893	39	198	n	n	CCONJ
dpc-4893	39	199	(	(	PUNCT
dpc-4893	39	200	%	%	INTJ
dpc-4893	39	201	):	):	PUNCT
dpc-4893	39	202	cyclosporin	cyclosporin	NOUN
dpc-4893	39	203	phototherapy	phototherapy	NOUN
dpc-4893	39	204	methotrexate	methotrexate	VERB
dpc-4893	39	205	acitretin	acitretin	PROPN
dpc-4893	39	206	22	22	NUM
dpc-4893	39	207	(	(	PUNCT
dpc-4893	39	208	81.5	81.5	NUM
dpc-4893	39	209	%	%	NOUN
dpc-4893	39	210	)	)	PUNCT
dpc-4893	39	211	11	11	NUM
dpc-4893	39	212	(	(	PUNCT
dpc-4893	39	213	40.7	40.7	NUM
dpc-4893	39	214	%	%	NOUN
dpc-4893	39	215	)	)	PUNCT
dpc-4893	39	216	10	10	NUM
dpc-4893	39	217	(	(	PUNCT
dpc-4893	39	218	37.0	37.0	NUM
dpc-4893	39	219	%	%	NOUN
dpc-4893	39	220	)	)	PUNCT
dpc-4893	39	221	10	10	NUM
dpc-4893	39	222	(	(	PUNCT
dpc-4893	39	223	37.0	37.0	NUM
dpc-4893	39	224	%	%	NOUN
dpc-4893	39	225	)	)	PUNCT
dpc-4893	39	226	7	7	NUM
dpc-4893	39	227	(	(	PUNCT
dpc-4893	39	228	25.9	25.9	NUM
dpc-4893	39	229	%	%	NOUN
dpc-4893	39	230	)	)	PUNCT
dpc-4893	39	231	biologics	biologic	NOUN
dpc-4893	39	232	,	,	PUNCT
dpc-4893	39	233	n	n	CCONJ
dpc-4893	39	234	(	(	PUNCT
dpc-4893	39	235	%	%	INTJ
dpc-4893	39	236	):	):	PUNCT
dpc-4893	39	237	naive	naive	ADJ
dpc-4893	39	238	adalimumab	adalimumab	NOUN
dpc-4893	39	239	secukinumab	secukinumab	NOUN
dpc-4893	39	240	ustekinumab	ustekinumab	PROPN
dpc-4893	39	241	guselkumab	guselkumab	PROPN
dpc-4893	39	242	ixekizumab	ixekizumab	PROPN
dpc-4893	39	243	brodalumab	brodalumab	NOUN
dpc-4893	39	244	etanercept	etanercept	NOUN
dpc-4893	39	245	golimumab	golimumab	PROPN
dpc-4893	39	246	risankizumab	risankizumab	PROPN
dpc-4893	39	247	tildrakizumab	tildrakizumab	NOUN
dpc-4893	39	248	18	18	NUM
dpc-4893	39	249	(	(	PUNCT
dpc-4893	39	250	66.7	66.7	NUM
dpc-4893	39	251	%	%	NOUN
dpc-4893	39	252	)	)	PUNCT
dpc-4893	39	253	9	9	NUM
dpc-4893	39	254	(	(	PUNCT
dpc-4893	39	255	33.3	33.3	NUM
dpc-4893	39	256	%	%	NOUN
dpc-4893	39	257	)	)	PUNCT
dpc-4893	39	258	13	13	NUM
dpc-4893	39	259	(	(	PUNCT
dpc-4893	39	260	48.1	48.1	NUM
dpc-4893	39	261	%	%	NOUN
dpc-4893	39	262	)	)	PUNCT
dpc-4893	39	263	7	7	NUM
dpc-4893	39	264	(	(	PUNCT
dpc-4893	39	265	25.9	25.9	NUM
dpc-4893	39	266	%	%	NOUN
dpc-4893	39	267	)	)	PUNCT
dpc-4893	39	268	4	4	NUM
dpc-4893	39	269	(	(	PUNCT
dpc-4893	39	270	14.8	14.8	NUM
dpc-4893	39	271	%	%	NOUN
dpc-4893	39	272	)	)	PUNCT
dpc-4893	39	273	2	2	NUM
dpc-4893	39	274	(	(	PUNCT
dpc-4893	39	275	7.4	7.4	NUM
dpc-4893	39	276	%	%	NOUN
dpc-4893	39	277	)	)	PUNCT
dpc-4893	39	278	2	2	NUM
dpc-4893	39	279	(	(	PUNCT
dpc-4893	39	280	7.4	7.4	NUM
dpc-4893	39	281	%	%	NOUN
dpc-4893	39	282	)	)	PUNCT
dpc-4893	39	283	1	1	NUM
dpc-4893	39	284	(	(	PUNCT
dpc-4893	39	285	3.7	3.7	NUM
dpc-4893	39	286	%	%	NOUN
dpc-4893	39	287	)	)	PUNCT
dpc-4893	39	288	1	1	NUM
dpc-4893	39	289	(	(	PUNCT
dpc-4893	39	290	3.7	3.7	NUM
dpc-4893	39	291	%	%	NOUN
dpc-4893	39	292	)	)	PUNCT
dpc-4893	39	293	1	1	NUM
dpc-4893	39	294	(	(	PUNCT
dpc-4893	39	295	3.7	3.7	NUM
dpc-4893	39	296	%	%	NOUN
dpc-4893	39	297	)	)	PUNCT
dpc-4893	39	298	1	1	NUM
dpc-4893	39	299	(	(	PUNCT
dpc-4893	39	300	3.7	3.7	NUM
dpc-4893	39	301	%	%	NOUN
dpc-4893	39	302	)	)	PUNCT
dpc-4893	39	303	1	1	NUM
dpc-4893	39	304	(	(	PUNCT
dpc-4893	39	305	3.7	3.7	NUM
dpc-4893	39	306	%	%	NOUN
dpc-4893	39	307	)	)	PUNCT
dpc-4893	39	308	biologics	biologic	NOUN
dpc-4893	39	309	failure	failure	NOUN
dpc-4893	39	310	,	,	PUNCT
dpc-4893	39	311	n	n	CCONJ
dpc-4893	39	312	(	(	PUNCT
dpc-4893	39	313	%	%	INTJ
dpc-4893	39	314	):	):	PUNCT
dpc-4893	39	315	1	1	NUM
dpc-4893	39	316	failure	failure	NOUN
dpc-4893	39	317	2	2	NUM
dpc-4893	39	318	failures	failure	NOUN
dpc-4893	39	319	3	3	NUM
dpc-4893	39	320	+	+	NUM
dpc-4893	39	321	failures	failure	NOUN
dpc-4893	39	322	10	10	NUM
dpc-4893	39	323	(	(	PUNCT
dpc-4893	39	324	37.0	37.0	NUM
dpc-4893	39	325	%	%	NOUN
dpc-4893	39	326	)	)	PUNCT
dpc-4893	39	327	2	2	NUM
dpc-4893	39	328	(	(	PUNCT
dpc-4893	39	329	14.8	14.8	NUM
dpc-4893	39	330	%	%	NOUN
dpc-4893	39	331	)	)	PUNCT
dpc-4893	39	332	2	2	NUM
dpc-4893	39	333	(	(	PUNCT
dpc-4893	39	334	14.8	14.8	NUM
dpc-4893	39	335	%	%	NOUN
dpc-4893	39	336	)	)	PUNCT
dpc-4893	39	337	adverse	adverse	ADJ
dpc-4893	39	338	events	event	NOUN
dpc-4893	39	339	,	,	PUNCT
dpc-4893	39	340	n	n	CCONJ
dpc-4893	39	341	(	(	PUNCT
dpc-4893	39	342	%	%	INTJ
dpc-4893	39	343	):	):	PUNCT
dpc-4893	39	344	axillary	axillary	ADJ
dpc-4893	39	345	candidiasis	candidiasis	NOUN
dpc-4893	39	346	1	1	NUM
dpc-4893	39	347	(	(	PUNCT
dpc-4893	39	348	3.7	3.7	NUM
dpc-4893	39	349	%	%	NOUN
dpc-4893	39	350	)	)	PUNCT
dpc-4893	39	351	1	1	NUM
dpc-4893	39	352	(	(	PUNCT
dpc-4893	39	353	3.7	3.7	NUM
dpc-4893	39	354	%	%	NOUN
dpc-4893	39	355	)	)	PUNCT
dpc-4893	39	356	pasi	pasi	NOUN
dpc-4893	39	357	:	:	PUNCT
dpc-4893	39	358	psoriasis	psoriasis	NOUN
dpc-4893	39	359	area	area	NOUN
dpc-4893	39	360	and	and	CCONJ
dpc-4893	39	361	severity	severity	NOUN
dpc-4893	39	362	index	index	NOUN
dpc-4893	39	363	;	;	PUNCT
dpc-4893	39	364	w	w	NOUN
dpc-4893	39	365	:	:	PUNCT
dpc-4893	39	366	week	week	NOUN
dpc-4893	39	367	.	.	PUNCT
dpc-4893	40	1	*	*	PUNCT
dpc-4893	40	2	mean	mean	VERB
dpc-4893	40	3	and	and	CCONJ
dpc-4893	40	4	sd	sd	NOUN
dpc-4893	40	5	are	be	AUX
dpc-4893	40	6	specified	specify	VERB
dpc-4893	40	7	for	for	ADP
dpc-4893	40	8	all	all	DET
dpc-4893	40	9	the	the	DET
dpc-4893	40	10	quantitative	quantitative	ADJ
dpc-4893	40	11	variables	variable	NOUN
dpc-4893	40	12	.	.	PUNCT
dpc-4893	41	1	vijayakumars	vijayakumar	NOUN
dpc-4893	41	2	sticky	sticky	ADJ
dpc-4893	41	3	note	note	NOUN
dpc-4893	41	4	marked	mark	VERB
dpc-4893	41	5	set	set	VERB
dpc-4893	41	6	by	by	ADP
dpc-4893	41	7	vijayakumars	vijayakumar	NOUN
dpc-4893	41	8	vijayakumars	vijayakumar	NOUN
dpc-4893	41	9	sticky	sticky	ADJ
dpc-4893	41	10	note	note	NOUN
dpc-4893	41	11	marked	mark	VERB
dpc-4893	41	12	set	set	VERB
dpc-4893	41	13	by	by	ADP
dpc-4893	41	14	vijayakumars	vijayakumar	NOUN
dpc-4893	41	15	vijayakumars	vijayakumar	NOUN
dpc-4893	41	16	sticky	sticky	ADJ
dpc-4893	41	17	note	note	NOUN
dpc-4893	41	18	marked	mark	VERB
dpc-4893	41	19	set	set	VERB
dpc-4893	41	20	by	by	ADP
dpc-4893	41	21	vijayakumars	vijayakumar	NOUN
dpc-4893	41	22	vijayakumars	vijayakumar	NOUN
dpc-4893	41	23	sticky	sticky	ADJ
dpc-4893	41	24	note	note	NOUN
dpc-4893	41	25	marked	mark	VERB
dpc-4893	41	26	set	set	VERB
dpc-4893	41	27	by	by	ADP
dpc-4893	41	28	vijayakumars	vijayakumar	NOUN
dpc-4893	41	29	vijayakumars	vijayakumar	NOUN
dpc-4893	41	30	sticky	sticky	ADJ
dpc-4893	41	31	note	note	NOUN
dpc-4893	41	32	marked	mark	VERB
dpc-4893	41	33	set	set	VERB
dpc-4893	41	34	by	by	ADP
dpc-4893	41	35	vijayakumars	vijayakumar	NOUN
dpc-4893	41	36	research	research	NOUN
dpc-4893	41	37	letter	letter	NOUN
dpc-4893	42	1	|	|	ADV
dpc-4893	42	2	dermatol	dermatol	ADJ
dpc-4893	42	3	pract	pract	NOUN
dpc-4893	42	4	concept	concept	NOUN
dpc-4893	42	5	.	.	PUNCT
dpc-4893	43	1	2025;15(1):4893	2025;15(1):4893	NUM
dpc-4893	43	2	3	3	NUM
dpc-4893	43	3	therapy	therapy	NOUN
dpc-4893	43	4	for	for	ADP
dpc-4893	43	5	obese	obese	ADJ
dpc-4893	43	6	patients	patient	NOUN
dpc-4893	43	7	with	with	ADP
dpc-4893	43	8	moderate	moderate	ADJ
dpc-4893	43	9	-	-	PUNCT
dpc-4893	43	10	to	to	ADP
dpc-4893	43	11	-	-	PUNCT
dpc-4893	43	12	severe/	severe/	NOUN
dpc-4893	43	13	difficultto	difficultto	ADJ
dpc-4893	43	14	-	-	PUNCT
dpc-4893	43	15	treat	treat	NOUN
dpc-4893	43	16	psoriasis	psoriasis	NOUN
dpc-4893	43	17	.	.	PUNCT
dpc-4893	44	1	future	future	ADJ
dpc-4893	44	2	studies	study	NOUN
dpc-4893	44	3	with	with	ADP
dpc-4893	44	4	larger	large	ADJ
dpc-4893	44	5	cohorts	cohort	NOUN
dpc-4893	44	6	and	and	CCONJ
dpc-4893	44	7	longer	long	ADV
dpc-4893	44	8	follow	follow	VERB
dpc-4893	44	9	-	-	PUNCT
dpc-4893	44	10	up	up	ADP
dpc-4893	44	11	periods	period	NOUN
dpc-4893	44	12	are	be	AUX
dpc-4893	44	13	necessary	necessary	ADJ
dpc-4893	44	14	to	to	PART
dpc-4893	44	15	further	far	ADV
dpc-4893	44	16	validate	validate	VERB
dpc-4893	44	17	these	these	DET
dpc-4893	44	18	results	result	NOUN
dpc-4893	44	19	.	.	PUNCT
dpc-4893	45	1	references	reference	NOUN
dpc-4893	45	2	1	1	NUM
dpc-4893	45	3	.	.	PUNCT
dpc-4893	45	4	megna	megna	PROPN
dpc-4893	45	5	m	m	PROPN
dpc-4893	45	6	,	,	PUNCT
dpc-4893	45	7	di	di	X
dpc-4893	45	8	costanzo	costanzo	PROPN
dpc-4893	45	9	l	l	PROPN
dpc-4893	45	10	,	,	PUNCT
dpc-4893	45	11	argenziano	argenziano	ADJ
dpc-4893	45	12	,	,	PUNCT
dpc-4893	45	13	et	et	PROPN
dpc-4893	45	14	al	al	PROPN
dpc-4893	45	15	.	.	PROPN
dpc-4893	45	16	effectiveness	effectiveness	NOUN
dpc-4893	45	17	and	and	CCONJ
dpc-4893	45	18	safety	safety	NOUN
dpc-4893	45	19	of	of	ADP
dpc-4893	45	20	secukinumab	secukinumab	NOUN
dpc-4893	45	21	in	in	ADP
dpc-4893	45	22	italian	italian	ADJ
dpc-4893	45	23	patients	patient	NOUN
dpc-4893	45	24	with	with	ADP
dpc-4893	45	25	psoriasis	psoriasis	NOUN
dpc-4893	45	26	:	:	PUNCT
dpc-4893	45	27	an	an	DET
dpc-4893	45	28	84	84	NUM
dpc-4893	45	29	week	week	NOUN
dpc-4893	45	30	,	,	PUNCT
dpc-4893	45	31	multicenter	multicenter	NOUN
dpc-4893	45	32	,	,	PUNCT
dpc-4893	45	33	retrospective	retrospective	ADJ
dpc-4893	45	34	real	real	ADJ
dpc-4893	45	35	-	-	PUNCT
dpc-4893	45	36	world	world	NOUN
dpc-4893	45	37	study	study	NOUN
dpc-4893	45	38	.	.	PUNCT
dpc-4893	46	1	expert	expert	NOUN
dpc-4893	46	2	opin	opin	NOUN
dpc-4893	46	3	biol	biol	NOUN
dpc-4893	46	4	ther	ther	ADV
dpc-4893	46	5	.	.	PUNCT
dpc-4893	47	1	2019;19:855–861	2019;19:855–861	NOUN
dpc-4893	47	2	.	.	PUNCT
dpc-4893	48	1	doi	doi	NOUN
dpc-4893	48	2	:	:	PUNCT
dpc-4893	48	3	10.1080/14712598	10.1080/14712598	NUM
dpc-4893	48	4	.2019.1622678	.2019.1622678	PROPN
dpc-4893	48	5	.	.	PUNCT
dpc-4893	49	1	pmid	pmid	NOUN
dpc-4893	49	2	:	:	PUNCT
dpc-4893	49	3	31140882	31140882	NUM
dpc-4893	49	4	.	.	PUNCT
dpc-4893	50	1	2	2	X
dpc-4893	50	2	.	.	X
dpc-4893	50	3	gargiulo	gargiulo	PROPN
dpc-4893	50	4	l	l	NOUN
dpc-4893	50	5	,	,	PUNCT
dpc-4893	50	6	ibba	ibba	ADJ
dpc-4893	50	7	l	l	NOUN
dpc-4893	50	8	,	,	PUNCT
dpc-4893	50	9	malagoli	malagoli	NOUN
dpc-4893	50	10	p	p	NOUN
dpc-4893	50	11	,	,	PUNCT
dpc-4893	50	12	et	et	PROPN
dpc-4893	50	13	al	al	PROPN
dpc-4893	50	14	.	.	PROPN
dpc-4893	50	15	brodalumab	brodalumab	PROPN
dpc-4893	50	16	for	for	ADP
dpc-4893	50	17	the	the	DET
dpc-4893	50	18	treatment	treatment	NOUN
dpc-4893	50	19	of	of	ADP
dpc-4893	50	20	plaque	plaque	NOUN
dpc-4893	50	21	psoriasis	psoriasis	NOUN
dpc-4893	50	22	in	in	ADP
dpc-4893	50	23	a	a	DET
dpc-4893	50	24	real	real	ADJ
dpc-4893	50	25	-	-	PUNCT
dpc-4893	50	26	life	life	NOUN
dpc-4893	50	27	setting	setting	NOUN
dpc-4893	50	28	:	:	PUNCT
dpc-4893	50	29	a	a	DET
dpc-4893	50	30	3	3	NUM
dpc-4893	50	31	years	year	NOUN
dpc-4893	50	32	multicenter	multicenter	NOUN
dpc-4893	50	33	retrospective	retrospective	ADJ
dpc-4893	50	34	study	study	NOUN
dpc-4893	50	35	-	-	PUNCT
dpc-4893	50	36	il	il	PROPN
dpc-4893	50	37	pso	pso	PROPN
dpc-4893	50	38	(	(	PUNCT
dpc-4893	50	39	italian	italian	ADJ
dpc-4893	50	40	landscape	landscape	NOUN
dpc-4893	50	41	psoriasis	psoriasis	NOUN
dpc-4893	50	42	)	)	PUNCT
dpc-4893	50	43	.	.	PUNCT
dpc-4893	51	1	front	front	PROPN
dpc-4893	51	2	med	med	PROPN
dpc-4893	51	3	(	(	PUNCT
dpc-4893	51	4	lausanne	lausanne	PROPN
dpc-4893	51	5	)	)	PUNCT
dpc-4893	51	6	.	.	PUNCT
dpc-4893	52	1	2023;10:1196966	2023;10:1196966	X
dpc-4893	52	2	.	.	X
dpc-4893	52	3	doi	doi	NOUN
dpc-4893	52	4	:	:	PUNCT
dpc-4893	52	5	10.3389	10.3389	NUM
dpc-4893	52	6	/fmed.2023.1196966	/fmed.2023.1196966	NOUN
dpc-4893	52	7	.	.	PUNCT
dpc-4893	53	1	pmid	pmid	NOUN
dpc-4893	53	2	:	:	PUNCT
dpc-4893	53	3	37469659	37469659	NUM
dpc-4893	53	4	.	.	PUNCT
dpc-4893	54	1	figure	figure	NOUN
dpc-4893	54	2	1	1	NUM
dpc-4893	54	3	.	.	PUNCT
dpc-4893	54	4	psoriasis	psoriasis	NOUN
dpc-4893	54	5	area	area	NOUN
dpc-4893	54	6	severity	severity	NOUN
dpc-4893	54	7	index	index	NOUN
dpc-4893	54	8	(	(	PUNCT
dpc-4893	54	9	pasi	pasi	NOUN
dpc-4893	54	10	)	)	PUNCT
dpc-4893	54	11	responses	response	NOUN
dpc-4893	54	12	at	at	ADP
dpc-4893	54	13	follow	follow	NOUN
dpc-4893	54	14	-	-	PUNCT
dpc-4893	54	15	up	up	ADP
dpc-4893	54	16	visits	visit	NOUN
dpc-4893	54	17	.	.	PUNCT
dpc-4893	55	1	pasi	pasi	NOUN
dpc-4893	55	2	75	75	NUM
dpc-4893	55	3	,	,	PUNCT
dpc-4893	55	4	90	90	NUM
dpc-4893	55	5	and	and	CCONJ
dpc-4893	55	6	100	100	NUM
dpc-4893	55	7	responses	response	NOUN
dpc-4893	55	8	after	after	ADP
dpc-4893	55	9	4	4	NUM
dpc-4893	55	10	,	,	PUNCT
dpc-4893	55	11	16	16	NUM
dpc-4893	55	12	and	and	CCONJ
dpc-4893	55	13	24	24	NUM
dpc-4893	55	14	weeks	week	NOUN
dpc-4893	55	15	of	of	ADP
dpc-4893	55	16	bimekizumab	bimekizumab	NOUN
dpc-4893	55	17	treatment	treatment	NOUN
dpc-4893	55	18	.	.	PUNCT
dpc-4893	56	1	3	3	X
dpc-4893	56	2	.	.	X
dpc-4893	56	3	galluzzo	galluzzo	PROPN
dpc-4893	56	4	m	m	PROPN
dpc-4893	56	5	,	,	PUNCT
dpc-4893	56	6	marcelli	marcelli	PROPN
dpc-4893	56	7	l	l	NOUN
dpc-4893	56	8	,	,	PUNCT
dpc-4893	56	9	vellucci	vellucci	PROPN
dpc-4893	56	10	l	l	NOUN
dpc-4893	56	11	,	,	PUNCT
dpc-4893	56	12	et	et	PROPN
dpc-4893	56	13	al	al	PROPN
dpc-4893	56	14	.	.	PROPN
dpc-4893	56	15	guselkumab	guselkumab	NOUN
dpc-4893	56	16	for	for	ADP
dpc-4893	56	17	treatment	treatment	NOUN
dpc-4893	56	18	of	of	ADP
dpc-4893	56	19	moderate	moderate	ADJ
dpc-4893	56	20	-	-	PUNCT
dpc-4893	56	21	to	to	ADP
dpc-4893	56	22	-	-	PUNCT
dpc-4893	56	23	severe	severe	ADJ
dpc-4893	56	24	plaque	plaque	NOUN
dpc-4893	56	25	psoriasis	psoriasis	NOUN
dpc-4893	56	26	:	:	PUNCT
dpc-4893	56	27	real	real	ADJ
dpc-4893	56	28	-	-	PUNCT
dpc-4893	56	29	life	life	NOUN
dpc-4893	56	30	effectiveness	effectiveness	NOUN
dpc-4893	56	31	and	and	CCONJ
dpc-4893	56	32	drug	drug	NOUN
dpc-4893	56	33	-	-	PUNCT
dpc-4893	56	34	survival	survival	NOUN
dpc-4893	56	35	for	for	ADP
dpc-4893	56	36	up	up	ADP
dpc-4893	56	37	to	to	PART
dpc-4893	56	38	148	148	NUM
dpc-4893	56	39	weeks	week	NOUN
dpc-4893	56	40	.	.	PUNCT
dpc-4893	57	1	expert	expert	NOUN
dpc-4893	57	2	opin	opin	NOUN
dpc-4893	57	3	biol	biol	NOUN
dpc-4893	57	4	ther	ther	ADV
dpc-4893	57	5	.	.	PUNCT
dpc-4893	58	1	2023;23:371–381	2023;23:371–381	X
dpc-4893	58	2	.	.	PUNCT
dpc-4893	59	1	doi	doi	NOUN
dpc-4893	59	2	:	:	PUNCT
dpc-4893	59	3	10.1080/14712598.2023.2194485	10.1080/14712598.2023.2194485	NUM
dpc-4893	59	4	.	.	PUNCT
dpc-4893	60	1	pmid	pmid	NOUN
dpc-4893	60	2	:	:	PUNCT
dpc-4893	60	3	36971507	36971507	NUM
dpc-4893	60	4	.	.	PUNCT
dpc-4893	61	1	4	4	NUM
dpc-4893	61	2	.	.	NOUN
dpc-4893	61	3	mastorino	mastorino	PROPN
dpc-4893	61	4	l	l	PROPN
dpc-4893	61	5	,	,	PUNCT
dpc-4893	61	6	susca	susca	PROPN
dpc-4893	61	7	s	s	PROPN
dpc-4893	61	8	,	,	PUNCT
dpc-4893	61	9	megna	megna	PROPN
dpc-4893	61	10	m	m	PROPN
dpc-4893	61	11	,	,	PUNCT
dpc-4893	61	12	et	et	PROPN
dpc-4893	61	13	al	al	PROPN
dpc-4893	61	14	.	.	PROPN
dpc-4893	61	15	risankizumab	risankizumab	PROPN
dpc-4893	61	16	shows	show	VERB
dpc-4893	61	17	high	high	ADJ
dpc-4893	61	18	efficacy	efficacy	NOUN
dpc-4893	61	19	and	and	CCONJ
dpc-4893	61	20	maintenance	maintenance	NOUN
dpc-4893	61	21	in	in	ADP
dpc-4893	61	22	improvement	improvement	NOUN
dpc-4893	61	23	of	of	ADP
dpc-4893	61	24	response	response	NOUN
dpc-4893	61	25	until	until	ADP
dpc-4893	61	26	week	week	NOUN
dpc-4893	61	27	52	52	NUM
dpc-4893	61	28	.	.	PUNCT
dpc-4893	62	1	dermatol	dermatol	NOUN
dpc-4893	62	2	ther	ther	ADV
dpc-4893	62	3	.	.	PUNCT
dpc-4893	63	1	2022;35	2022;35	X
dpc-4893	63	2	.	.	PUNCT
dpc-4893	63	3	doi	doi	NOUN
dpc-4893	63	4	:	:	PUNCT
dpc-4893	64	1	10.1111	10.1111	NUM
dpc-4893	64	2	/	/	SYM
dpc-4893	64	3	dth.15378	dth.15378	NOUN
dpc-4893	64	4	.	.	PUNCT
dpc-4893	65	1	pmid	pmid	NOUN
dpc-4893	65	2	:	:	PUNCT
dpc-4893	65	3	35156278	35156278	NUM
dpc-4893	65	4	.	.	PUNCT
dpc-4893	66	1	5	5	NUM
dpc-4893	66	2	.	.	X
dpc-4893	67	1	wang	wang	PROPN
dpc-4893	67	2	j	j	PROPN
dpc-4893	67	3	,	,	PUNCT
dpc-4893	67	4	yu	yu	PROPN
dpc-4893	67	5	y	y	PROPN
dpc-4893	67	6	,	,	PUNCT
dpc-4893	67	7	liu	liu	PROPN
dpc-4893	67	8	l	l	PROPN
dpc-4893	67	9	,	,	PUNCT
dpc-4893	67	10	et	et	PROPN
dpc-4893	67	11	al	al	PROPN
dpc-4893	67	12	.	.	PUNCT
dpc-4893	68	1	global	global	ADJ
dpc-4893	68	2	prevalence	prevalence	NOUN
dpc-4893	68	3	of	of	ADP
dpc-4893	68	4	obesity	obesity	NOUN
dpc-4893	68	5	in	in	ADP
dpc-4893	68	6	patients	patient	NOUN
dpc-4893	68	7	with	with	ADP
dpc-4893	68	8	psoriasis	psoriasis	NOUN
dpc-4893	68	9	:	:	PUNCT
dpc-4893	68	10	an	an	DET
dpc-4893	68	11	analysis	analysis	NOUN
dpc-4893	68	12	in	in	ADP
dpc-4893	68	13	the	the	DET
dpc-4893	68	14	past	past	ADJ
dpc-4893	68	15	two	two	NUM
dpc-4893	68	16	decades	decade	NOUN
dpc-4893	68	17	.	.	PUNCT
dpc-4893	69	1	autoimmun	autoimmun	PROPN
dpc-4893	69	2	rev	rev	PROPN
dpc-4893	69	3	.	.	PROPN
dpc-4893	70	1	2024	2024	NUM
dpc-4893	70	2	jun;23(6):103577	jun;23(6):103577	PROPN
dpc-4893	70	3	.	.	PUNCT
dpc-4893	70	4	doi	doi	PROPN
dpc-4893	70	5	:	:	PUNCT
dpc-4893	70	6	10.1016	10.1016	NUM
dpc-4893	70	7	/	/	SYM
dpc-4893	70	8	j.autrev	j.autrev	PROPN
dpc-4893	70	9	.2024.103577	.2024.103577	PROPN
dpc-4893	70	10	.	.	PUNCT
dpc-4893	71	1	pmid	pmid	NOUN
dpc-4893	71	2	:	:	PUNCT
dpc-4893	71	3	39009055	39009055	NUM
dpc-4893	71	4	.	.	PUNCT
dpc-4893	72	1	6	6	NUM
dpc-4893	72	2	.	.	X
dpc-4893	72	3	gargiulo	gargiulo	PROPN
dpc-4893	72	4	l	l	PROPN
dpc-4893	72	5	,	,	PUNCT
dpc-4893	72	6	narcisi	narcisi	ADV
dpc-4893	72	7	a	a	DET
dpc-4893	72	8	,	,	PUNCT
dpc-4893	72	9	ibba	ibba	ADJ
dpc-4893	72	10	l	l	NOUN
dpc-4893	72	11	,	,	PUNCT
dpc-4893	72	12	et	et	PROPN
dpc-4893	72	13	al	al	PROPN
dpc-4893	72	14	.	.	PROPN
dpc-4893	72	15	effectiveness	effectiveness	NOUN
dpc-4893	72	16	and	and	CCONJ
dpc-4893	72	17	safety	safety	NOUN
dpc-4893	72	18	of	of	ADP
dpc-4893	72	19	bimekizumab	bimekizumab	NOUN
dpc-4893	72	20	for	for	ADP
dpc-4893	72	21	the	the	DET
dpc-4893	72	22	treatment	treatment	NOUN
dpc-4893	72	23	of	of	ADP
dpc-4893	72	24	plaque	plaque	NOUN
dpc-4893	72	25	psoriasis	psoriasis	NOUN
dpc-4893	72	26	:	:	PUNCT
dpc-4893	72	27	a	a	DET
dpc-4893	72	28	real	real	ADJ
dpc-4893	72	29	-	-	PUNCT
dpc-4893	72	30	life	life	NOUN
dpc-4893	72	31	multicenter	multicenter	NOUN
dpc-4893	72	32	study	study	NOUN
dpc-4893	72	33	-	-	PUNCT
dpc-4893	72	34	il	il	PROPN
dpc-4893	72	35	pso	pso	PROPN
dpc-4893	72	36	(	(	PUNCT
dpc-4893	72	37	italian	italian	ADJ
dpc-4893	72	38	landscape	landscape	NOUN
dpc-4893	72	39	psoriasis	psoriasis	NOUN
dpc-4893	72	40	)	)	PUNCT
dpc-4893	72	41	.	.	PUNCT
dpc-4893	73	1	front	front	PROPN
dpc-4893	73	2	med	med	PROPN
dpc-4893	73	3	(	(	PUNCT
dpc-4893	73	4	lausanne	lausanne	PROPN
dpc-4893	73	5	)	)	PUNCT
dpc-4893	73	6	.	.	PUNCT
dpc-4893	74	1	2023;10:1243843	2023;10:1243843	X
dpc-4893	74	2	.	.	PUNCT
dpc-4893	74	3	doi	doi	NOUN
dpc-4893	74	4	:	:	PUNCT
dpc-4893	74	5	10.3389	10.3389	NUM
dpc-4893	74	6	/	/	SYM
dpc-4893	74	7	fmed.2023	fmed.2023	PROPN
dpc-4893	74	8	.1243843	.1243843	NOUN
dpc-4893	74	9	.	.	PUNCT
dpc-4893	75	1	pmid	pmid	NOUN
dpc-4893	75	2	:	:	PUNCT
dpc-4893	75	3	37614958	37614958	NUM
dpc-4893	75	4	.	.	PUNCT
dpc-4893	76	1	vijayakumars	vijayakumar	VERB
dpc-4893	76	2	sticky	sticky	ADJ
dpc-4893	76	3	note	note	NOUN
dpc-4893	76	4	marked	mark	VERB
dpc-4893	76	5	set	set	VERB
dpc-4893	76	6	by	by	ADP
dpc-4893	76	7	vijayakumars	vijayakumar	NOUN
dpc-4893	76	8	vijayakumars	vijayakumar	NOUN
dpc-4893	76	9	sticky	sticky	ADJ
dpc-4893	76	10	note	note	NOUN
dpc-4893	76	11	marked	mark	VERB
dpc-4893	76	12	set	set	VERB
dpc-4893	76	13	by	by	ADP
dpc-4893	76	14	vijayakumars	vijayakumar	NOUN
dpc-4893	76	15	vijayakumars	vijayakumar	NOUN
dpc-4893	77	1	sticky	sticky	ADJ
dpc-4893	77	2	note	note	NOUN
dpc-4893	77	3	marked	mark	VERB
dpc-4893	77	4	set	set	VERB
dpc-4893	77	5	by	by	ADP
dpc-4893	77	6	vijayakumars	vijayakumar	NOUN